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ABSTRACT 
Background 
An estimated one in four couples globally suffers from infertility or fertility related 
issues and rate of global infertility is about 10-15%. Despite the best optimization of assisted 
reproductive technique the pregnancy rate is not more than 30%. Poor understanding of the 
complex molecular interactions between the blastocyst and the receptive endometrium is one 
of the major reasons for unexplained infertility. Understanding the molecular mechanisms of 
human embryo implantation helps in improving pregnancy rates, management of infertility 
issues and helps in regulation of fertility by novel methods. 
Aim 
The overall aim of this thesis is to expand the understanding of various factors that 
affects endometrial receptivity and human embryo implantation process. The specific aims of 
the thesis are to explore the role of leukemia inhibitory factor (LIF) in implantation and 
viability of the human embryo and, to study the actions of ulipristal acetate (UPA) and two 
low doses of mifepristone on endometrial receptivity and human embryo implantation using 
an in vitro three-dimensional (3D) endometrial co-culture model, in addition to study 
progesterone regulated transcriptomic signature in epithelial and stromal compartments. 
Materials, methods and results 
Study 1 is an in vitro exploratory study of the role of LIF in human embryo implantation 
and its viability by using potent LIF inhibitor, polyethylene glycated leukemia inhibitory 
factor antagonist (PEGLA) in a 3D endometrial cell co-culture model. Inhibition of LIF by 
PEGLA significantly reduced blastocyst attachment to endometrial constructs and triggered 
apoptosis of blastocysts by down regulating embryonic AKT and up regulating caspase 3 as 
analyzed by immunofluorescence and RTPCR. Studies 2 and 3 were exploratory studies on 
endometrial receptivity and human embryo implantation process after treatment with 200 
ng/ml UPA, a dose used for emergency contraception (study 2) and two low doses of 
mifepristone (0.5µM and 0.05µM, study 3) using an in vitro 3D endometrial cell co-culture 
model. Selected endometrial receptivity markers were analyzed by RTPCR from the 
endometrial constructs. The main findings of study 2 were that there was no significant 
difference in the blastocyst attachment rate to endometrial constructs when compared 
between UPA treated group (5/10 blastocysts attached) and control group (7/10 blastocysts 
attached). Of the studied 17 endometrial receptivity markers, HBEGF and IL6 were 
significantly upregulated and HAND2, OPN, CALCR and FGF2 were down- regulated with 
UPA treatment. The main findings of study 3 were that none of the embryos in 0.5µM of 
mifepristone attached to the endometrial constructs, whereas 4 out of 10 in 0.05 µM group 
and 7 out of 10 embryos in the control group attached to the cultures. Most of the studied 
receptivity markers were significantly altered with mifepristone exposure in a similar 
direction in both the treatment groups. Study 4 explored large-scale progesterone regulated 
transcriptomic signature in epithelial and stromal compartments by laser capture 
microdissection and microarray analysis in receptive and non-receptive (treatment with 200 
mg mifepristone on LH+2) endometrium. Expression of Metallothioneins (MT1G and 
MT2A) and Ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) was 
significantly downregulated in both stromal cells and glands, whereas SFRP4 was 
upregulated. ENPP3 protein and mRNA expression was significantly down regulated in 
epithelial compartment of non-receptive endometrium, but no stromal immunostaining was 
detected in either receptive or non-receptive endometrium. ENPP3 protein was observed in 
glycosylated form in both the endometrial tissue lysates and uterine fluid. The expression 
pattern of ENPP3 was similar to progesterone secretion - high in mid-secretory and low in 
proliferative phase. In vitro functional assay using 3D cell cultures confirmed the receptivity 
of the endometrial construct falling in line with the expression of ENPP3. 
Conclusion 
LIF plays a critical role in the process of human embryo implantation and viability of the 
blastocyst. UPA at a dose used as emergency contraception (30 mg single dose) does not 
affect endometrial receptivity and embryo implantation. Mifepristone at a concentration of 
0.5µM affected endometrial receptivity and inhibited embryo implantation whereas 0.05µM 
mifepristone affected the studied genes known to be involved in endometrial receptivity, but 
had no effect on embryo implantation. ENPP3 is proposed as a novel molecular marker of 
progesterone regulated endometrial receptivity. 
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I. Introduction 
Fertility is the natural ability to produce offspring. World Health Organization (WHO) 
defines infertility as “a disease of reproductive system defined by the failure to achieve a 
clinical pregnancy after 12 months or more of regular unprotected sexual intercourse (six 
months if the woman is over age 35) ‘or’ inability to carry a pregnancy to a live birth”. 
Infertility is classified as primary infertility – a woman who never conceived, and secondary 
infertility – a failure to conceive after previous pregnancy. Each of the following factors 
contributes equally (about 1/3rd) to infertility - female partners, male partners, or the 
combination of both. Many different causes of infertility include age, genetic abnormalities, 
hormonal abnormalities, lack of regular ovulation, anatomical defects like blocked fallopian 
tubes, problems with uterine cavity, cervical defects, peritoneal factors, endometriosis, 
uterine fibroids, polycystic ovary syndrome or unexplained (1). An estimated one in four 
couples, numbering 48.5 million couples globally suffered from infertility or subfertility 
related issues in the year 2010 alone (2).  
Research in reproductive sciences has made the management of fertility or sub fertility 
easier in the recent years. As we celebrate the Noble Prize 2010 (RG Edwards, 2010) 
technique of Assisted Reproductive Technology (ART) which has added a new dimension in 
treating childless couples, we should notice that the rate of global infertility is still about 10-
15% (Reproductive Health Outlook, 2005). Despite the best optimization of critical events of 
ART, pregnancy rate is not more than 30% (3). As the issue of infertility causes great 
emotional and economic consequences in the economically developed world, the issue of 
fertility regulation is a major burden in the economically developing countries. One of the 
reasons for the unexplained infertility is poor understanding of the synchronized, complex 
molecular interactions taking place between the pre-implantation embryo and the receptive 
endometrium during the window of implantation (WOI). 
 
1.1 Uterus  
Uterus is divided into an upper part- the body and a lower part – the cervix that is 
continuous with upper vagina.  It is composed of three layers – perimetrium which is the 
outside layer of serosa, myometrium, the middle muscular layer and endometrium, the inner 
layer. Endometrium is a complex and dynamic tissue that undergoes regeneration, 
differentiation, and shedding in each menstrual cycle during the reproductive life of a woman.  
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1.1.1 Endometrium 
Histologically endometrium is divided into the bottom one-third permanent stratum 
basalis and the superficial two-thirds stratum functionalis. The upper functionalis layer is 
highly sensitive to the fluctuating ovarian hormones, estrogen and progesterone, and it is this 
layer that degenerates and shed during the menstrual bleeding (if there is no implantation) 
during each menstrual cycle. Post menstruation, functionalis layer is regenerated from basalis 
layer. Endometrium is composed of mostly stromal & epithelial cells (luminal and glandular) 
and to a lesser extent, stem cells, endothelial cells and immune cells - macrophages and 
uterine natural killer cells (uNK cells). 
1.1.1.1 Epithelial compartment 
The endometrial epithelial cells play a key role in embryo implantation by selectively 
allowing the embryo implantation during WOI. Outside WOI these cells are refractory to 
embryo implantation due to the presence of hormonally controlled protective glycocalyx 
molecules (4). Epithelial compartment is classified into the superficial luminal epithelial layer 
and glandular epithelium within the stromal compartment. Luminal epithelium serves as a 
barrier against infections and as a surface for blastocyst attachment and implantation. 
Glandular epithelium is composed of a single layer of ciliated columnar epithelial cells that 
are phenotypically different. Morphology of glandular epithelium change constantly in 
accordance with the ovarian hormone secretions throughout various phases of menstrual 
cycle. During proliferative phase where estrogen is dominant, the glands appear straight and 
long, during secretory phase the glands become coiled and produce secretions under the 
influence of progesterone.  
1.1.1.2 Stromal compartment 
Stromal cells, fibroblastic in nature, are located in the connective tissue of the 
endometrium that is made up of proteoglycans and collagen. Thickness of stromal 
compartment varies under the ovarian hormonal influences. Estrogen increases the 
proliferation of stromal cells during the proliferative phase; progesterone in the secretory 
phase reduces stromal proliferation. Upon successful blastocyst implantation the stromal cells 
complete decidualization and terminally differentiate (5). Stromal cells are loosely packed in 
the functionalis layer to facilitate blastocyst implantation whereas densely packed in the 
basalis layer of the endometrium. Stromal cells secrete various tissue-remodeling substances 
that include matrix metalloproteinases (MMP-2 and MMP-4), tissue inhibitors of 
metalloproteinases (TIMPs), growth factors and cytokines. MMPs expression in the stroma is 
mainly regulated by a cell surface glycoprotein present in the luminal and glandular 
epithelium known as extracellular matrix metalloproteinase inducer (EMMPRIN)(6). 
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1.1.1.3 Immune cells 
The predominant immune cells - macrophages/dendritic cells, T-Lymphocytes, 
neutrophils, mast cells and uNK cells are located in the stromal compartment. Sex steroid 
hormones influence immune system in female reproductive tract, though the leucocytes lack 
receptors for estrogen and progesterone. Interestingly, the immune cells provide immunity 
against vaginal pathogens in lower tract whereas immune tolerance towards the sperm and 
embryo is maintained in upper tract (7). Very few B-lymphocytes are seen in endometrium 
throughout the menstrual cycle in comparison to T lymphocytes.  
Elevated levels of uNK cells is observed in late secretory phase and further increased 
during early pregnancy (8). A positive correlation is observed between the circulating 
progesterone levels and uNK cells and a reduced number of uNK cells are seen in 
endometrium with anti progestin Asoprisnil treatment. With antiprogestin treatment, IL-5 
pathway is identified to be involved in the development, function and differentiation of 
immature uNK to mature uNK cells (9). Though uNK cells lack the progesterone receptors, it 
is suggested that progesterone acts indirectly through cytokines and soluble factors secreted 
by stromal cells (10). Macrophages and dendritic cells are seen throughout all the phases of 
menstrual cycle, significant number of macrophages is especially seen around the glands 
during menstrual phase and notably at the implantation site.   
1.1.1.4 Endothelial cells 
Sex hormones regulate endothelial cell population in the endometrial vasculature. 
Angiogenesis is formation of new blood vessels either growing from pre-existing vessels or 
by intussusception i.e. formation of new vessels by division of pre existing vessels (11). 
Angiogenesis plays a crucial role in menstrual cycle during endometrial maturation and 
regeneration after menstruation. Vascular endothelial growth factor (VEGF) is considered the 
most important stimulator of angiogenesis and has been shown to inhibit apoptosis in 
endothelial cells in vitro.  
 Endothelial cells in human endometrium express progesterone receptor (PR) 
and estrogen receptor-β (ERβ). However, estrogen also acts indirectly by enhancing the 
expression of VEGF and fibroblast growth factor -2 (FGF-2). The role of progesterone in 
angiogenesis is controversial, in vitro it has been reported to have stimulatory as well as an 
inhibitory effect on endothelial cell proliferation (12). It has been proposed that progesterone 
acts through paracrine factors/mechanisms secreted by stromal cells that are close to vessels 
and treatment with anti-progestin mifepristone is shown to reduce the tube formation in 
endothelial cells (13).  
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 1.1.1.5 Endometrial stem cells 
Based on the unique properties of endometrium like tissue repair, regeneration and 
destruction during menstruation, it is believed that there is a population of tissue stem cells 
that is responsible for the regeneration of the functionalis layer of endometrium from the 
basalis layer. Stem cells are clonogenic, self-renewable, possess potential for differentiation 
and are proliferative. The stem cell population in endometrium includes mesenchymal 
stem/stromal cells (MSCs), bone marrow derived stem cells and side population cells (SP 
cells). To date, no specific markers have been identified for isolating endometrial epithelial 
progenitor cells, however recently stage–specific embryonic antigen-1 (SSEA-1/CD15) (13) 
was proposed as a marker for epithelial stem cells. SSEA-1+ cells exhibit adult stem cell 
properties like increased telomerase activity, longer telomeres; however it is not yet known 
whether the SSEA-1+ cells have clonogenic or self-renewal properties in the epithelial 
compartment. The minimum criteria for a cell to be identified as MSC is that the cell has to 
coexpress CD146 and CD140b (PDGFRβ) along with a single perivascular marker, sushi 
domain containing 2 (SUSD2) (W5C5 antibody) (14-16).  
SP cells vary during each phase of menstrual cycle being highest in proliferative phase 
and least in late secretory phase (17). SP cells characteristically have rich ABCG2 (ATP 
binding cassette subfamily G member 2) expression and are located in functionalis and 
basalis layers near the vascular walls (18). Interestingly, the concept of bone marrow derived 
stem cells arises from the experimental animals and studies tracing donor specific markers 
following bone marrow transplantation; yet the role of these cells in endometrial regeneration 
is unknown (19, 20).  Of many pathways involved in regulation of stem cell systems in 
uterus, Wnt/β-catenin signaling pathway is considered as a key pathway (21). Detailed 
knowledge of this pathway would help in understanding other stem cell specific molecular 
mechanisms involved in normal physiology and pathology of uterus. 
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1.2 Menstrual cycle 
Menstrual cycle comprises the cyclical changes that take place in ovary, uterus, vagina 
and mammary glands once every 28 days during the reproductive age of the woman. 
Menstrual cycle is further classified as ovarian cycle, endometrial/uterine cycle, vaginal cycle 
and cyclical changes that occur in mammary glands (Figure 1).  
1.2.1 Ovarian cycle  
Ovarian cycle is the sequential changes that occur in the ovary during the menstrual 
cycle and is further classified into follicular phase and luteal phase with day of ovulation on 
the14th day in a 28 days menstrual cycle.  
During the follicular phase, under the influence of follicular stimulating hormone (FSH), 
6-12 primary follicles start developing at the beginning of every cycle. Following early 
follicular phase, the primary follicles secrete follicular fluid rich in estrogens and the fluid 
cavity known as antrum appears. Pituitary FSH along with high estrogen concentration from 
the antral follicle promotes the appearance of LH receptors and stimulates the secretion of 
Luteinizing hormone (LH) in the granulosa cells of ovum. Subsequently estrogens, in 
combination with LH promote the growth of antral follicle and increase the size by 3-4 times.  
By the second week, one of the follicles becomes dominant follicle and all other follicles 
undergo atresia. The dominant follicle secretes more estrogen so that the plasma 
concentration of estrogen starts increasing, and the dominant follicle by the time of ovulation 
reaches a diameter of 1.5 -2 cm and is termed as mature follicle.  
Increased estrogen concentration during the late follicular phase stimulates gonadotropin 
releasing hormone (GnRH) secretion and enhances the LH hormone secretion from the 
pituitary leading to a surge in the production of LH known as LH peak. The midcycle LH 
surge induces the ovulation, which occurs approximately on day 14, 10-12 hours post LH 
peak, and 24-36 hours after peak estrogen level.  
In the luteal phase, LH surge stimulates the remaining granulosa cells and theca cells of 
the mature follicle to transform into lutein cells that are filled with lipid inclusions and appear 
yellow in color. This process is called ‘luteinization’ and the complete follicle is termed as 
corpus luteum. If fertilization fails to occur 7-8 days of ovulation, the corpus luteum starts 
involuting and looses its secretory activity becoming corpus albicans. As a result plasma 
concentrations of progesterone and estrogens start declining and the inhibitory effect of these 
ovarian hormones on GnRH secretion is released, starting a new cycle with rising FSH and 
LH hormones. On successful fertilization and implantation, the corpus luteum is maintained 
as corpus luteum of pregnancy that secretes high levels of progesterone and estrogen to 
maintain pregnancy.  
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Figure 1 : Menstrual cycle 
1.2.2 Endometrial cycle 
Endometrial cycle is the sequential morphological and molecular changes that take place 
in the endometrium during the menstrual cycle. Endometrial cycle is divided into 
proliferative and secretory phase separated by the day of ovulation. During the first five days 
of cycle, endometrium sheds off into the menstrual blood. After the menstrual phase, the 
endometrium is less than 2 mm thickness and under the influence of estrogens, proliferation 
of glands, blood vessels, stroma and luminal epithelium takes place, termed as proliferative 
phase, and the endometrium reaches a thickness of 4-5 mm by the day of ovulation.  
During secretory phase or progestational phase, corpus luteum secretes much higher 
quantities of progesterone than estrogen. Estrogen during this phase causes slight additional 
cellular proliferation in endometrium and high progesterone concentration cause marked 
swelling and increase in the secretory activity of the cells. Under the influence of 
progesterone, glands increase in tortuosity and large quantity of secretory substances is 
deposited in the glands. The cytoplasm of stromal cells are packed with glycogen and lipids 
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and transform the structure, a process termed as decidualization. Increased blood supply 
ensues to endometrium with developing secretory activity. The purpose of all these observed 
changes of the secretory phase is to produce a secretory endometrium containing sizeable 
amounts of accumulated nutrients to provide optimal conditions for implantation of the 
embryo and for accommodating subsequent embryo development.  
1.2.3 Decidualization 
Decidualization is the morphological changes that are observed in stromal cells during 
the late luteal phase. The process starts around cycle day 23 and is independent of the 
presence or absence of blastocyst. If implantation occurs, decidualization plays an important 
role in formation of placenta by mediating the invasion of trophoblasts, and lack of 
decidualization lead to a failed placentation (22). Decidualization is characterized by 
transformation of elongated stromal cells or fibroblasts into larger and circular phenotype by 
the accumulation of glycogen and lipids, secreting numerous cellular products. Further 
changes that are seen during decidualization include presence of leukocytes and vascular 
changes in the maternal arteries. If no implantation occurs, the decidualized endometrial 
lining is shed in the menstruation. 
 In vitro, the stromal cells can be decidualized by progesterone treatment of 
estrogen primed cells, ligands of cyclic AMP (cAMP) pathway like Prostaglandin E2 
(PGE2), LH, FSH and Relaxin hormone (23, 24). cAMP alone can induce decidualization if 
the stromal cells are obtained from the late luteal phase biopsy. In general prolactin (PRL), 
insulin like growth factor binding protein 1 (IGFBP1) and notch1 are considered as markers 
of decidualization.  
1.3 Endometrial dating 
Noyes endometrial histological dating (25) was considered a gold standard for 
endometrial dating. Hitchmann and Adler were the first to observe histological changes in the 
endometrium, which were further amplified by Schroeder, Novak, O’Leary and Bartelmez 
(25). Frankel and R.Meyer correlated these findings with the coincidental changes in ovary 
(25). Morphometric analysis was an improved version of histological dating proposed by 
Johannison in 1982 (26). It is an objective and quantitative technique that related the results 
to peripheral hormone levels. A total of 17 morphometric measurements are studied in this 
analysis and are compared with the chronological dating as defined by LH surge and shows a 
good correlation (r = 0.98). It is more accurate and reliable to date endometrium in 
comparison to criteria by Noyes et.al (27). To overcome the improbability of accuracy and 
utility with the histological dating other approaches such as whole genome molecular 
phenotyping (28), non invasive testing by high resolution endovaginal ultrasonography (29, 
30) are employed and have been shown with good predictive value, better than histological 
dating.  
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1.4 Fertilization 
Fertilization is the process of the union of human ovum with sperm and this normally 
takes place in the ampulla of fallopian tube (Figure 2).  
1.4.1 Mechanism of fertilization 
Immediately after ovulation, around 14th day of menstrual cycle of a normal 28 day 
cycle, the ovum is released and carried into the ampulla of fallopian tube along with the 
cumulus oophorus. Ovary by secreting chemotactants attracts the sperms and GnRH that is 
produced locally by fallopian tube assists binding of sperm to the protective layer of ovum, 
the zona pellucida. The acrosomal cap of sperm secretes a trypsin like enzyme, acrosin, 
which disperses the corona of the ovum and permits the attachment of sperm to zona 
pellucida. 
Penetration of zona pellucida by the successful sperm creates a block to entry of other 
sperms in sequential steps such as uptake of Ca++ into ovum, plasma membrane 
depolarization and release of proteases and glycosidases from the secretory granules of ovum 
and finally alters the zona surface glycoprotein, ZP3 that rejects the additional sperms rather 
than attracting. Therefore it prevents complete entrance of partially penetrated sperms, 
thereby preventing polyploidy, a condition in which more than two sets of homologous 
chromosomes is seen. 
Figure 2: Mechanism of fertilization 
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On successful fertilization, the ovum undergoes second meiotic division releasing the 
polar body, leaving the ovum in a haploid state i.e. with 23 chromosomes. Fusion of sperm 
releases the nuclear chromatin material that combines with the haploid nucleus of ovum 
giving rise to diploid individual or zygote i.e. 46 chromosomes. 
1.4.2 In vitro fertilization (IVF) and embryo grading  
Since the evolution of IVF, embryologists grade the embryo for embryo transfer (ET) 
during IVF treatment based on the morphology and cleavage rates. Because of limitations in 
morphologic grading, the embryo secretion and metabolic consumption of the embryo spent 
media may give a better picture about the quality of the embryos (31).  A positive correlation 
is seen with the nutrient uptake from the culture media and high morphological grade of 
embryo; however its use is limited because of high cost and need for highly trained experts 
(32). In view of these limitations, a non-invasive, rapid and consistent method was tried based 
on the metabolomics of the embryo-spent medium by Raman spectroscopy (33). However, in 
most IVF clinics Gardner and Schoolcraft’s classification is widely used for assessing the 
quality of blastocyst and blastocyst with a minimum grade of 3BB suggested for ET clinically 
(34). 
 In Gardner grading system, each blastocyst is assigned a quality score based on 
three criteria namely 1) Blastocyst development stage- based on expansion 2) Inner cell mass 
(ICM) score 3) Trophectoderm (TE) score. 
Table 1: Gardner and Schoolcraft’s Embryo grading system 
Expansion 
grade Blastocyst development and stage status 
1 Blastocoel cavity less than half the volume of the embryo 
2 Blastocoel cavity more than half the volume of the embryo 
3 Full blastocyst, cavity completely filling the embryo 
4 Expanded blastocyst, cavity larger than the embryo, with thinning of the shell 
5 Hatching out of the shell 
6 Hatched out of the shell 
ICM Grade Inner cell mass quality 
A Many cells, tightly packed 
B Several cells, loosely grouped 
C Very few cells 
TE grade Trophectoderm quality 
A Many cells, forming a cohesive layer 
B Few cells, forming a loose epithelium 
C Very few large cells 
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1.5. Endometrial receptivity 
Endometrial receptivity is defined as the time during which the endometrium is favorable 
for embryo implantation. This occurs in luteal phase approximately from 6th to 10th day after 
LH surge (35), which is also termed as window of implantation (36). During this period 
endometrium undergoes various molecular and structural changes influenced by hormones, 
growth factors and various molecular mediators. Any defects during this period, either in the 
embryo or the endometrium, will lead to implantation failure. In light of both ethical and 
technical issues, it is very difficult to identify site and mechanisms of implantation in vivo. 
Therefore, majority knowledge about implantation and embryo development is obtained from 
animal models; however, the limitation is that the reproductive physiology is different in 
different species, hence it is difficult to generalize these models to the process in humans. 
The availability of biomarkers of endometrial receptivity is increasing exponentially 
owing to recent studies and advances that have opened avenues for the discovery of new 
biomarkers; however, a single unequivocal marker has not yet been established. 
 
1.5.1 Biomarkers of endometrial receptivity and implantation 
1.5.1.1 HORMONES 
1.5.1.1.1 Estrogen 
Priming of the endometrium by estrogen results in endometrial proliferation and 
induction of PRs that allow progesterone subsequently to induce endometrial receptivity. For 
normal development of the endometrium, presence of estrogen is important, although not 
necessarily in a large quantity (37). A high concentration of serum estrogen increases the risk 
of pregnancy complications such as abnormal placentation (38).  Estrogen acts through the 
estrogen receptors (ER), which exist in two isoforms (ERα and ERβ). Of the two isoforms, 
ERα is dominant; in the case of a lack of ERα, uterus becomes hypoplastic and shows no 
response to estrogen treatment (39). No such effects are seen in the absence of ERβ (40).  
Estrogen binds to membrane-associated G-protein-coupled receptor (GPCR) and 
promotes the release of nascent pro-heparin binding-epidermal growth factor (HB-EGF) that 
binds to epidermal growth factor receptor (EGFR) and activates downstream mitogen-
activated protein kinases (MAPK) (41), resulting in a crosstalk with growth factors or insulin 
like growth factor-1 (IGF-1) cascades, stimulating proliferation.  
Calbindin-D28k, an intracellular calcium-binding protein, is regulated by estrogen and is 
involved in the regulation of endometrial receptivity by altering the concentration of 
intracellular calcium ions (42). Calbindin-D28k expression is high during the proliferative 
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phase and at the time of sexual maturity, estrogen inhibits its expression in the uterus, 
suggesting that calbindin-D28k plays an important role in endometrial receptivity (43). A 
similar intracellular calcium-binding protein, Calmodulin (CaM) play a significant role in the 
contraction of smooth muscles in myometrium and a pivotal role in the proliferation of a 
variety of cells. Estrogens in combination with chorionic gonadotropins also increase the 
expression of Notch1, a decidualization marker (44). Absence of Notch-1 leads to apoptosis 
of stromal fibroblasts cells, uterine sloughing, and a reduction in cell survival and 
differentiation, which lead to decidualization defects affecting the pregnancy (45). 
 
1.5.1.1.2 Progesterone 
Progesterone is the key hormone that drives endometrial receptivity and interruption of 
luteal phase progesterone using anti-progestins makes the endometrium non receptive. Role 
of progesterone in maintenance of endometrial receptivity and pregnancy is originated from 
the progesterone receptor knockout mice (46). Progesterone mediates its actions in the target 
organs by progesterone receptors (PR). Affinity of progesterone towards PR is less than the 
affinity of estrogen towards its estrogen receptors (47). At high concentrations even 
glucocorticoids can bind to PR and in the same fashion at high concentrations even 
progesterone binds to androgen receptors and glucocorticoid receptors (47). PRs exist in two 
isoforms PRA and PRB; in endometrium the ratio of these two isoforms vary constantly 
during menstrual cycle (48). Isoform PRC also exists that is lesser known (49). Of the two 
isoforms, PRB is a stronger transcriptional activator whereas transcriptional activity of PRA is 
cell and gene specific (50). Inhibition of decidualization is seen in a PRA knockout mice, 
suggesting an important role of PRA in decidualization (51) whereas uterine responses to 
progesterone are not affected in a PRB knockout mice (52).  
 
1.5.1.1.3 Human Chorionic Gonadotropin (hCG) 
hCG is the first confirmed marker of human trophoblast cells and is composed of α and β 
subunits that are non-covalently linked together. It is secreted by cytotrophoblast cells and 
induces extravillous cytotrophoblasts proliferation and invasion by inhibiting TGF-β 
receptors, thus preventing the apoptosis of trophoblast cells (53). Presence of hCG is the 
principal detection method in the pregnancy confirmation tests. hCG maintains the 
pregnancy, until the placenta takes over. hCG acts through luteinizing 
hormone/choriogonadotropin receptor that is present on the corpus luteum. Apart from this, 
hCG plays an important role in angiogenesis, decidualization, immune modulation and 
remodeling of extracellular matrix in the endometrium. 
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1.5.1.1.4 Corticotropin releasing hormone (CRH) 
CRH is a neuropeptide that is secreted from the hypothalamus in response to stress 
reaction and is a principal regulator of Hypothalamo-Pituitary Axis (HPA). Endometrium 
during blastocyst implantation shows characteristics of acute inflammatory response from the 
invading semi-allograft blastocyst; however once implantation is successful, the embryo 
suppresses this reaction. CRH also plays a critical role on the maternal immune system to 
prevent graft vs. host reaction by slaying of activated T cells through Fas-Fas Ligand 
interactions. Blockage of CRH receptors by an antagonist antalarmin, reduces the 
implantation sites by 70% in animal models. On the other hand, in vitro, CRH receptor 
blockade increases the trophoblast invasion by 60% suggesting a role in regulation of 
trophoblast invasion (54). A defective CRH/CRH receptor system is usually seen in recurrent 
implantation failure (RIF) patients, placental defects and preeclampsia conditions.  
Intrauterine administration of autologous CRH-treated peripheral blood mononuclear 
cells increased the positive pregnancy by 44% in RIF patients, suggesting a potential role for 
CRH in treating the RIF patients (55).  
 
1.5.1.1.5 Calcitonin 
Calcitonin / thyrocalcitonin is a known potential regulator of implantation and a marker 
of endometrial receptivity (56, 57). It plays a critical role in calcium homeostasis in the body 
by reducing serum calcium concentration in response to hypercalcemia and also acts counter 
to the parathyroid hormone. During WOI a high concentration of calcitonin in endometrium 
is seen (58) and inhibition of calcitonin synthesis by antagonists in mice reduces the 
implantation rates by 50-80% (56). It is hypothesized that calcitonin upregulates the 
expression of integrin β3 in endometrial epithelial cells facilitating implantation (59). In vitro, 
incubation of blastocysts with 10nM calcitonin has been shown to accelerate differentiation 
of blastocyst cells suggesting a role in embryonic development (60). Expression of calcitonin 
is regulated by progesterone and progesterone through calcitonin modulates the expression of 
E-Cadherins. 
 
1.5.1.1.6 Leptin 
Leptin, known as satiety hormone, is secreted from adipose cells and is encoded by ob 
gene. It plays an important role in endometrial receptivity and implantation by down-
regulating γ-ENaC (Epithelial sodium channels) by activating STAT3 signalling pathways 
(61). ENaCs play a key role in regulating endometrial receptivity and an altered expression 
has been shown to cause impaired endometrial receptivity and implantation failures (62). 
High levels of leptin are seen in patients with recurrent miscarriage and RIF (63). 
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1.5.1.2 Pinopodes 
Pinopodes are typical bleb like protrusions on the uterine luminal epithelial apical 
surface that appear during the window of receptivity (64). Role of ovarian hormones in the 
development of pinopodes is variable; appearance of pinopodes is strictly progesterone 
dependent whereas supra physiological levels of estrogens cause loss of pinopodes and 
physiological levels of estrogen favor the pinopode formation (65). The exact role of 
pinopodes remains unknown; however pinopodes seem to have various roles in blastocyst 
implantation that include mediation of endocytosis, exchange of fluids and facilitate the 
adhesion of blastocyst. It has been shown that pinopodes are the preferred site for blastocyst 
attachment (66). Pinopodes also release secretory vesicles that are rich in LIF (67), an 
important cytokine which influences endometrial receptivity by regulating trophoblast 
function and vascular formation in placenta. 
 
1.5.1.3 Mucins 
Mucins form a protective biofilm on the surface of endometrial epithelium and also 
maintain local molecular microenvironment (68). MUC1, MUC16 and to a lesser extent 
MUC6 have been shown to be expressed in endometrium among all the cloned human 
mucins (69-71).  
 MUC1 also known as Episialin/ Epithelial Membrane Antigen, is synthesized 
in rough endoplasmic reticulum and becomes glycosylated in golgi apparatus (72). DNA 
Methylation studies reveal that MUC1 gene is regulated by DNA methylation and Histone 
H3 Lysine9 (H3-K9) modification at the MUC1 promoter site (73). Significant reduction of 
MUC1 expression is observed in women with recurrent pregnancy loss (74). MUC16 a 
component of non-receptive luminal epithelium, prevents trophoblast adhesion and during the 
implantation at the time of pinopode formation, MUC16 is eliminated favoring adhesion of 
trophoblast cells (71). 
 
1.5.1.4 Cell adhesion molecules (CAMs)  
CAMs are transmembrane receptors that are mainly involved in cell adhesion.  CAMs 
are composed of three domains, an intracellular domain, an extracellular domain and a 
transmembrane domain. CAMs are subdivided into 4 groups namely Cadherins, Integrins, 
Selectins and Immunoglobulin superfamily (IgSF). Cadherins and selectins are calcium 
dependent for execution of their function whereas IgSF and Integrins are calcium 
independent. Apart from the mentioned CAMs, Trophinin in combination with tastin and 
bystin plays an important role in endometrial receptivity and implantation. 
  
14 
 
1.5.1.4.1 Cadherins 
Cadherins are type-1 transmembrane glycoproteins and are calcium ion dependent to 
serve their function. Primary function of cadherins is formation of adherens junction to 
promote cell-to-cell adhesion, also involved in tissue structure maintenance and in cellular 
movement. Cadherins are classified into Epithelial-Cadherins (E-Cadherin), Placental-
Cadherins (P-Cadherins) and Neural-Cadherins (N-Cadherin), which are tissue specific (75). 
E-Cadherin is the most studied cadherin in endometrial receptivity and embryo implantation.  
E-cadherins are located in the adherens junctions on lateral side of epithelial plasma 
membrane that are critical in maintenance of these junctions (76). Expression of E-cadherins 
is high during the luteal phase (77). Precise role of E-Cadherin in human implantation is 
unknown, however any mutations in E-Cadherin gene lead to a defective preimplantation 
development in mice (78). E-Cadherins exhibit a dual role in endometrium. In pre-
implantation period, E-Cadherins increase the adhesiveness of the epithelial cells and avoid 
the implantation outside the WOI period. During implantation period a rise in progesterone 
increases the intracellular calcium ions mediated by the increase in endometrial calcitonin 
hormone expression, in turn the increased calcitonin decreases the expression of E-Cadherins 
making the epithelial cells less adhesive and enables epithelial cell dissociation facilitating 
the embryo implantation process (58, 79).  
Sirtuin 1 (SIRT1), a class III histone deacetylase, in vitro has been shown to improve 
implantation rates that are mediated by an increase in the expression of E-cadherins in a dose 
dependent manner. SIRT1 stimulating drugs such as resveratrol in in vitro experiments on 
cell lines using embryo implantation models demonstrated an improved implantation rate, the 
repressors of SIRT1 decreased the implantation by reducing E-cadherin expression (80). This 
indicates that the mentioned chemicals could be used as therapeutic targets for improving 
implantation process and a success in ART can be achieved, but with a caution that the 
pathophysiology of implantation varies between in vitro and in vivo and it would be 
interesting to explore this hypothesis in in vivo models. 
1.5.1.4.2 Integrins 
Integrins are family of transmembrane glycoproteins whose primary function is 
attachment of cell to extracellular matrix (ECM) and signal transduction from ECM to cell. 
αvβ3 integrin and its ligand osteopontin are the most studied of all integrins in the context of 
endometrial receptivity and implantation. αvβ3 is a receptor for vitronectin and is composed 
of integrin alpha V and integrin beta 3/ CD61. Immunohistochemical detection techniques 
show that αvβ3 and osteopontin are located in endometrial luminal epithelial surface that first 
interacts with the blastocyst (81). Receptors for integrins are also expressed on the blastocyst 
during implantation window (82).  Expression of integrins is seen highest during the 
implantation window and a blockade of αvβ3 receptors results in decreased number of 
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implantation sites in a mice model whereas in rabbit models implantation is inhibited (83, 
84).  
In a clinical trial, Integrins β1 and β3 along with serum estrogen and progesterone levels 
are suggested to be good biomarkers for determining optimal time for ET and in assessing 
endometrial receptivity (85). During implantation integrins β1 and β3 disassemble from site 
of focal adhesions and cause removal of luminal endometrial epithelial cells to facilitate 
implantation (86).   Apart from αvβ3, integrins such as Integrin β8 (87), αvβ5 (88) have an 
essential role in implantation process. Interestingly, in women with impaired fertility, 
expression of integrins α4β1, αVβ1 were upregulated in glandular epithelium and stroma (89) 
and in recurrent pregnancy loss a significant reduction of integrin expression is observed 
(90).  
 
1.5.1.4.3 Selectins 
Selectins are a family of heterophilic CAMs i.e. binding of extracellular domain of 
CAMs to ECM, that binds to mucins. Selectins are classified as Endothelial selectins (E-
Selectins), Leukocyte selectins (L-Selectins) and Platelet selectins (P-Selectins). Selectins 
play an important role in leucocyte transendothelial trafficking (91). The L-Selectin adhesion 
system i.e. L-Selectins and its oligosaccharide ligand MECA-79 plays an important role in 
implantation and is considered as most important pathway for embryo-endometrial 
interactions. L-Selectin receptors are expressed on the surface of blastocyst and the 
expression in endometrium is seen during the mid secretory phase particularly in pinopodes 
(92) suggesting a role in implantation.  
MECA-79 is predominantly present in the glandular compartment and seen throughout 
the menstrual cycle. However, an increased expression is seen during the mid secretory phase 
i.e. during WOI (93). Lack of MECA-79 expression during the mid secretory phase is seen in 
women with recurrent implantation failure (94). Higher expression of L-Selectin ligand is 
associated with an improved pregnancy outcome in women undergoing IVF and ET (95).  
 
1.5.1.4.4 Immunoglobulin superfamily (IgSF) 
Intercellular adhesion molecule-1 (ICAM-1)/CD54 is a transmembrane glycoprotein 
expressed on various cells such as fibroblasts, leukocytes, endothelial and epithelial cells. 
ICAM-1 contains a ligand for widely expressed integrin β2 and mediates cell adhesion, which 
is essential for different immunological functions such as natural killer cell mediated 
cytotoxicity and transendothelial migration of leukocytes (96). ICAM-1 is expressed 
throughout menstrual cycle at the apical surface of epithelial glands and stroma, whereas 
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upregulation in the expression is seen during the menstruation in stromal cells and a 
significantly reduced expression is seen in secretory endometrium of endometriosis patients 
(97).  
In serum and peritoneal fluid a circulating soluble form of ICAM-1 (sICAM-1) is seen as 
a result of shedding of transmembrane bound ICAM-1. Interferon-γ (IFN-γ) upregulates the 
expression of ICAM-1 in the endometrial stromal cell cultures and also allows the 
accumulation of sICAM-1 (98). Stromal cells of eutopic endometrium from women with 
endometriosis, when stimulated with IFN-γ, display an upregulation of sICAM-1. Altered 
expression of vascular CAM-1 (VCAM-1) and ICAM-1 are observed in women with 
endometriosis and ratio of soluble VCAM-1/ sICAM-1 is a promising biomarker for 
diagnosing endometriosis non-invasively (99). Higher levels of tissue ICAM-1 is seen in 
patients with recurrent pregnancy loss (100) and ICAM-1 plays an important role in 
endometriosis pathogenesis by facilitating escape from immunosurveillance, of the refluxed 
endometrial cells and allows them to spread and invade other locations (98).  
 Basigin / CD147/ EMMPRIN is a member of IgSF. It exists as component of 
receptor complex on trophoblast and is involved in the regulation of implantation, invasion 
and differentiation of trophoblast cells (101).  Knockout of BSG gene leads to infertility 
(102). 
 
1.5.1.4.5 Trophinin – Tastin – Bystin complex 
Trophinin is a CAM that is involved in initial attachment of embryo in the implantation 
process. In addition it mediates the cell adhesion between trophoblast cells and luminal 
epithelial cells. Peak expression is seen during the mid luteal phase and expression is also 
seen in trophectoderm cells of embryo and placenta.  
Trophinin in combination with tastin and bystin forms a complex that mediates the 
unique adhesion of embryo to luminal epithelium (103). It is hypothesized that cell adhesion 
mediated by trophinin induces the apoptosis of epithelial cells to facilitate invasion by 
trophoblast cells (104).  Decreased expression of trophinin leads to decreased implantation 
rates, as observed in endometriosis patients and infertile women (105, 106).  
Bystin and Tastin are cytoplasmic proteins that are expressed along with trophinin in 
trophoblast cells and endometrial epithelial cells at the site of implantation. Exact mechanism 
of action of this complex on endometrial receptivity and implantation is unclear and further 
studies on this complex provide more detailed insights into the molecular mechanism of 
implantation and may contribute to progress in reproductive medicine. 
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1.5.1.5 Cytokines 
Cytokines are group of small proteins (5-20kDa) that play an important role in cell 
signaling. Cytokines act as immunomodulating agents that are involved in autocrine, 
endocrine and paracrine signalling. They are produced by a broad range of cells in the body 
and are involved in multiple cell functions like proliferation, differentiation, play a key role in 
immune system, role in menstrual cycle and are also critical for implantation.  
 
1.5.1.5.1 Leukemia inhibitory factor (LIF) 
LIF is an Interleukin 6 class pro-inflammatory cytokine that play an important role in 
cell differentiation. It is normally expressed in trophectoderm of embryo and its receptor 
(LIFR-α/LIFR) is expressed throughout the inner cell mas in the blastocyst. In endometrium 
its expression is seen in the glandular compartment and is proven to be an important and first 
cytokine factor to be involved in the regulation of uterine receptivity.  
LIF binds to its receptor LIFR and forms a complex with gp130, a signal transducing 
subunit and a common receptor for IL-6, i.e. LIF-LIFR-gp130 complex, leading to activation 
of JAK/STAT and MAPK cascades in the epithelial cells and specifically luminal cells. The 
cascade of changes includes change in the epithelial polarity, angiogenesis, epithelial-
mesenchymal interactions, decidualization in stromal cells and inhibition of cell proliferation. 
Apart from the activation of JAK/STAT pathways, it also activates many important signalling 
pathways which are essential for implantation such as TGFβ signalling, FGF signalling, 
VEGF signalling, Wnt-β catenin signalling, PTEN signalling and Notch signalling. 
 Progesterone plays a significant role in regulation of LIF and administration of 
anti-progestin mifepristone after the day of ovulation is shown to reduce glandular LIF (107). 
LIF and LIFR play a critical role in various endometrial pathologies and diseases affecting 
fertility. In adenomyosis, a significant reduction in LIFR expression is seen, which reduces 
the STAT3 signalling pathways mediated by LIF and leads to declined implantation rates in 
women (108).  Similar abnormal levels of LIF are seen in women with unexplained fertility 
and RIF patients. Evidence of LIF and gp130 secretions in the uterine fluid opens a novel 
way for diagnosis of endometrial receptivity non-invasively that helps in predicting 
successful implantation in women treated with recombinant LIF (109). 
 
1.5.1.5.2 Interleukin-1 (IL-1) 
IL-1 cytokine family is a group of 11 cytokines and are key mediators of immune and 
inflammatory responses. In IL-1 knockout mice, which are fertile, an intraperitoneal injection 
  
18 
 
of IL-1R antagonist prevented blastocyst implantation by reducing the integrin expression in 
luminal epithelial cells (110), a similar phenomenon that is also seen in humans. An increased 
expression of integrin β3 is seen in the endometrial epithelial cell cultures supplemented with 
IL-1, a similar function is seen for IL-1β, which is mediated by secretion of leptin from 
epithelial cells (111, 112). In vitro, treatment of endometrial 3D cell cultures with 
mifepristone reduces the expression of IL-1 suggesting a regulation by progesterone (113).  
 
1.5.1.5.3 Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory cytokine as well as anti-inflammatory myokine that act 
through IL-6R and gp130 receptors. Expression of IL-6 & IL-6R is highest in mid to late 
secretory phase, strongest expression seen in the epithelial compartment (114). A predicted 
paracrine or autocrine role for IL-6 in implantation and endometrial receptivity is suggested 
since receptors for IL-6 are expressed by blastocyst and endometrium. Reduced sites of 
implantation and fertility were seen in IL-6 deficient mice, however disruption of IL-6 gene 
in mice did not affect the blastocyst implantation but the blastocysts were underdeveloped 
(115). 
 
1.5.1.6 Growth factors  
Growth factors are naturally occurring cell derived polypeptides that act as 
signalling molecules and stimulate the growth of the cell. Expression of receptors for 
various growth factors on the endometrium suggests an important role in maintaining 
endometrial receptivity and implantation.  
1.5.1.6.1 Transforming growth factor-β (TGF-β) 
TGF-β plays a significant role in tissue remodeling and reproductive processes and 
exists in TGF-β1, β2 and β3 isoforms. TGF-β1 & TGF-β3 are predominantly localized in 
both the epithelial and the stromal compartment whereas TGF-β2 is seen only in the 
stroma. Abundant expression of TGF-β in the endometrium suggests an active role in 
modulating the cellular events responsible for menstruation, decidualization, implantation 
and maintenance of pregnancy (116). TGF-β regulates endometrial remodeling in each 
menstrual cycle by acting through PI3K/AKT survival pathway along with inhibition of 
XIAP, an anti-apoptotic protein (117). Gargett et.al have demonstrated in cell cultures that 
inhibition of TGF-β receptor signalling promotes and maintains the stemness of 
endometrial MSCs (118).  
 TGF-β was shown to play a critical role in establishment and progression of 
various endometrial pathologies such as intra uterine adhesions, endometriosis, heavy 
menstrual bleedings and adenomyosis (119-121). 
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1.5.1.6.2 Insulin like growth factor (IGFs) 
IGFs are proteins that have high similarity in sequence to insulin that form a part of 
complex network in cell communications. IGFs bind to IGF Receptors (IGF1R and IGF2R) 
on cell surfaces for mediating their biological activity. IGFs consist of two ligands IGF1 
and IGF2. High expression of IGF1 is seen during the peri-implantation period and is 
assumed to be involved in the decidualization process (122) and enhances embryo 
development and quality. IGF2 is a known mediator of trophoblast function (123) and its 
expression in blood vessels near the implantation site suggests a role in angiogenesis (124). 
  
1.5.1.6.3 Colony stimulating factors (CSFs) 
CSFs include CSF1, CSF2 and CSF3. CSF1/ macrophage CSF (M-CSF) is a 
secreted cytokine that binds to CSF1 receptor (CSF-1R). It is presumed to be involved in 
development of placenta and decreased implantation rates are observed with mutation of 
CSF gene (125, 126). Decreased mRNA concentration of CSF1 is observed in patients with 
recurrent miscarriage (127) whereas an increased expression is documented in early 
endometriotic lesions or endometriosis (128, 129). 
 CSF2/ Granulocyte-Macrophage CSF (GM-CSF) is a monomeric 
glycoprotein secreted by NK cells, T-cells, endothelial cells, macrophages and fibroblasts. 
It is a potent inducer and activator of both macrophages and dendritic cells that play a 
crucial role in preeclampsia (130).  Insufficient CSF2 leads to impaired generation of T-cell 
mediated immunity at the onset of pregnancy, which may lead to infertility, miscarriage or 
pre-eclampsia (131).  
CSF3/ Granulocyte-CSF (G-CSF/GCSF), a glycoprotein that stimulates bone 
marrow to produce stem cells and granulocytes. An increased implantation rate and positive 
clinical pregnancies are reported with transvaginal perfusion of GCSF in IVF undergoing 
woman with thin endometrium or repeated IVF failures (132-134), however exact 
mechanism of action is unknown.   
1.5.1.6.4 Heparin binding –epidermal like growth factor (HB-EGF) 
It is a member of epidermal growth factor family that interacts with EGF receptor 
and TGF-α receptor. Expression is seen throughout the menstrual cycle, however increased 
expression is seen during the secretory phase and with particularly highest expression prior 
to implantation (135). Co-existence of HB-EGF in the glandular compartment and 
pinopodes at same time suggests an important role in attachment and invasion processes of 
implantation (136). Recently it is shown that HB-EGF stimulates EGFR/ERK signalling to 
promote Aquaporin 3 expression in trophoblast cells, which play a vital role in HB-EGF 
induced implantation (137). Reduced levels of HB-EGF protein expression is seen in mid 
secretory endometrium in women with unexplained infertility (138). 
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1.5.1.6.5 Keratinocyte growth factor (KGF) 
KGF / FGF7 is usually observed in epithelialization phase of wound healing. KGF 
is induced by stromally derived progesterone and also acts as progestomedin (139). In in 
vitro cultures KGF acts as a mitogen for epithelial cells. Peak expression of KGF during 
WOI stimulates the spiral artery growth that is essential for successful implantation, in 
addition to inhibition of apoptosis of the glands (140).  
 
1.5.1.7 Proteins 
1.5.1.7.1 Glycodelin  
Glycodelin/ Placental Protein 14 (PP14)/ Placental α2-macroglobulin/ progesterone 
dependent endometrial protein (PAEP) is a glycoprotein that has similar characteristics like 
integrin β3 and exists in three isoforms in amniotic fluid (Glycodelin-A), in seminal fluid 
(Glycodelin-S) and in follicular fluid (Glycodelin-F) (141). It plays a critical role in 
modulating maternal immune system to permit the fetal allograft by suppressing the 
cytolytic activity of CD8+ T lymphocytes (142). Increased expression of glycodelin is seen 
during the secretory phase and particularly during the WOI. Glycodelin-A is abundant in 
receptive endometrium (143) and also seen in the pinopodes of receptive endometrium. 
Clinically, reduced levels of glycodelin are observed in women with polycystic ovary 
syndrome (PCOS), endometriosis (144) and in RIF patients (145). 
 
1.5.1.7.2 Annexin IV (ANX4) 
ANX4 belongs to family of calcium-dependent phospholipid binding proteins and 
plays a role in the regulation of ion and water transport across epithelial cells in 
endometrium. Expression of ANX4 varies throughout the menstrual cycle, a weak 
expression is seen during the proliferative phase compared to mid and late secretory phase 
in glandular compartment. (146). Reduced ANX4 expression levels are observed in women 
with endometriosis suggesting a role in endometrial receptivity (147).  
 
1.5.1.7.3 CD9 or Motility related protein-1 (MRP1) 
CD9 / MRP1 is considered as one of the stem cell markers expressed in the 
epithelial glands. CD9 forms a complex with integrin α3 at cell contact sites and mediates 
integrin signalling in different processes such as cell proliferation, differentiation, motility 
and adhesions (148). Expression status of CD9 and integrin α3 provides valuable insights to 
the behavior of endometrial cancers; an aggressive behavior of endometrial tumors is 
observed in lack of CD9/MRP1 co-operation with integrins (149). CD9 regulates the 
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embryo invasion during implantation by acting through PI3K signalling (150) and severe 
fertility reduction is seen in CD9 deficient mice (151). 
 
1.5.1.7.4 CD98 
CD98 is a glycoprotein that is involved in amino acid transport and cell fusion. It 
forms multiple complexes with CD147, integrins β1, β3 and ICAM1. Its expression in 
epithelial cells is strictly restricted to implantation window in a hormone dependent fashion. 
Lack of CD98 affects the blastocyst adhesion (152) and lethal phenotypes resulted in mice 
with gene deletion for CD98 (153) suggesting that CD98 plays an important role in 
endometrial receptivity. 
 
1.5.1.7.5 CD43 
CD43 /Sialophorin/Leukosialin is a transmembrane cell surface protein that is 
localized in epithelial compartment during the time of implantation. It is involved in 
adhesion of blastocyst to luminal epithelial cells (154) and is regulated by combination of 
estrogen and progesterone (155). 
 
1.5.1.7.6 CD52 
CD52 or CAMPATH-1 antigen is a glycoprotein that is expressed on lymphocytes, 
sperms, epididymis and epithelial cells. In mouse endometrium, CD52 expression peaks 
during WOI and is expressed specifically in luminal epithelial cells. It plays a role in 
induction of ovulation that is stimulated by ovarian gonadotropic hormones and is 
associated with NKX2.2 pathways, which regulates expression of several cytokines 
including LIF (156). 
 
1.5.1.7.7 CD82 
CD82/ Metastasis suppressor/ KAI1 is a glycoprotein that has an anti-migratory 
function in tumor cells. A rise in expression of CD82 from proliferative to secretory is seen 
in human endometrium suggesting its regulation by progesterone. CD82 is localized to both 
the glandular and stromal compartment, being weakest in the stromal cells. It facilitates 
embryo adhesion to the endometrium through FAK signalling pathways (157). In addition, 
CD82 participates in intercellular communication with trophoblast cells thereby controlling 
trophoblast invasion (158). Altered levels of CD82 expression are observed in 
endometriosis patients implying a role in pathogenesis of endometriosis (159) and a 
decreased expression is seen in advanced endometrial cancers (160).  
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1.5.1.7.8 Galectins (Gal) 
Galectins are a family of proteins that are lectins having galactose-binding ability in 
addition to amino acids. Till date 15 isoforms of galectins have been discovered, however 
galectins 1 and gal 3 are the ones that are widely studied in the endometrium and to a lesser 
extent gal 9 and gal12. Galectins have a role in modulating the endometrial immune 
system, cell adhesion, chemotaxis and protection of endometrium from invading pathogens. 
Gal-1 is localized in the stroma and seen throughout the menstrual cycle being up regulated 
in late secretory phase and early pregnancy decidua whereas Gal-3 is localized in the 
glandular epithelium and follows same pattern as gal-1 and highly expressed during WOI 
(161).  
 
1.5.1.7.9 Osteopontin (OPN) 
OPN/ Bone Sialoprotein 1 (BSP1) is a secreted phosphoprotein 1 (SPP1) expressed 
on luminal epithelial cells and is a ligand for integrin αVβ3. Integrin αVβ3 through its 
ligand OPN mediates the adhesion of embryo to the luminal epithelium during 
implantation. It regulates the expression of FoxM1 (Forkhead box M1), which in turn 
activates ERK 1/2, and p38 signalling pathways leading to proliferation of cells (162). 
Significant presence of Osteopontin-αVβ3 complex in implantation suggests this complex 
as a biomarker of endometrial receptivity (163). In women with endometriosis, a decreased 
expression during WOI is observed suggesting an important role in infertility (164).  
 
1.5.1.7.10 Claudin 4 (CLDN4) 
Claudin 4 is an integral membrane protein that forms a part of tight junctions in the 
cells to form aqueous and ion-selective pores. Interestingly, combined immunolabeling of 
CLDN4-/LIF+ could serve as a potential biomarker to predict successful pregnancy outcome 
in women undergoing IVF (165). CLDN4 plays a significant role in pathogenesis of 
endometriosis and a decreased expression is seen in the ectopic endometrium (166). It is 
proposed that CLDN4 could serve as a useful biomarker for monitoring treatment of 
endometrial carcinomas as an abnormally high expression of CLDN4 is observed in various 
endometrial carcinomas (167). 
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1.5.1.8 ENZYMES 
1.5.1.8.1 Serum/Glucocorticoid regulated kinase 1 (SGK1) 
SGK1 is induced by progesterone and plays a role in ion and solute transport through 
ENaCs in luminal epithelial cells.  However, a decreased expression of SGK1 is seen during 
the WOI in the luminal epithelium and a rise in SGK1 levels during WOI is associated with 
inhibition of implantation in humans and mice (168), a similar observation is seen in women 
with unexplained infertility (169). Activation of SGK1 leads to inhibition of PI3K/AKT 
signalling pathways and activates ENaCs and other ion channels causing premature closure of 
receptivity, ultimately inhibiting embryo implantation (170). LEFTY-A, a known regulator of 
stemness and embryonic differentiation and a negative regulator of receptivity, has been 
shown that it activates and regulates the epithelial ENaCs acting through SGK1 thereby 
decreasing endometrial receptivity (171).   
 
1.5.1.8.2 Matrix metalloproteinases (MMPs) 
MMPs are calcium dependent zinc containing endopeptidases whose primary function 
is degradation of ECM proteins, cell proliferation, differentiation, apoptosis etc. MMPs and 
their inhibitors TIMPs play a critical role in implantation by ECM remodeling and are 
regulated by progesterone. Abnormal expression of MMPs is associated with disturbances in 
implantation and fertility. In women with impaired fertility, a high level of MMP2 expression 
is seen during WOI (172) and dysregulation of MMP2, MMP9 and TIMP1 results in 
infertility and early pregnancy loss (173). In addition, MMP2 promotes angiogenesis that is 
mediated through COX-2 and AKT signalling pathways and helps in endometriosis 
progression (174). 
 
1.5.1.8.3 Fucosyltransferases (FUT) 
Six members constitute this enzyme family (FUT3, FUT4, FUT5, FUT6, FUT7 and 
FUT9) that plays an important role in synthesis of fucosylated glycoconjugates that affect cell 
adhesion. In mice, FUT4, FUT7 and FUT9 show a peak expression during the day of 
implantation. In both in vitro and in vivo mice models, overexpression of FUT7 is shown to 
increase embryo adhesion and implantation rates (175). FUT4 via Wnt/beta-catenin 
signalling pathway promotes embryo adhesion and implantation and is considered as a 
general marker of endometrial receptivity (176).  
 
1.5.1.8.4 Tissue transglutaminase (tTG) 
tTG/TG2 is a calcium dependent enzyme of transglutaminase family.  A ten fold 
higher concentration of tTG activity is seen during the luteal phase implying a progesterone 
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regulation (177). tTGs through their interaction with fibronectin network participate in the 
adhesion events of implantation process by activating integrins signalling pathways (178).  
 
1.5.1.8.5 Monoamino oxidases (MAO) 
MAOs are enzymes that catalyze oxidation of monoamines and are found in the outer 
membrane of mitochondria. MAOs exists in two forms MAO-A and MAO-B that are both 
expressed in uterus (179). MAO-A seems to play a role in endometrial receptivity as its 
increased expression appears in the receptive phase of the glandular endometrium, 
particularly mid-luteal phase. It is presumed that MAO-A promotes implantation process by 
inhibiting 5-hydroxytryptamine, a potential toxic molecule (180). Lack of MAO-A 
expression results in decreased endometrial receptivity in infertile women. 
 
1.5.1.9 Transcription factors 
1.5.1.9.1 HOXA-10/HOXA-11/Homeobox genes (Hox) 
Hox genes encode proteins that are essential for embryonic morphogenesis and 
differentiation. Expression of HOXA-10 & HOXA-11 is observed in both the glandular and 
the stromal compartment, peak expression is seen during WOI. Hox plays an important role 
in implantation and any mutations of these genes result in failed implantations and infertility 
(181). HOXA-10 is essential for development of proper female reproductive tract, stromal 
decidualization and pinopode development. Impaired uterine development is seen in HOXA-
11 null mutant mice. In infertile women with intramural fibroids and endometriosis a reduced 
expression of HOXA-10 and HOXA-11 is seen (182). 
 
1.5.1.9.2 Forkhead box protein O1 (FOXO-1) 
FOXO-1 plays an important role in regulation of gluconeogenesis and glycogenolysis 
by insulin signalling. FOXO proteins regulate genes of proapoptosis, differentiation, DNA 
repair and are essential for progesterone receptors to bind target genes (183). FOXO1A is 
known for its critical role in decidualization. Overexpression of SGK1 decreases the 
transcription of FOXO1 and ultimately reduces the expression of prolactin, a key marker of 
decidualization (169). In addition, FOXO1 also increases IGFBP1 expression during 
decidualization by binding to insulin response element (IRE) in IGFBP1 promoter region. In 
PCOS patients a compensatory hyperinsulinemia is observed with unexplained infertility and 
it is hypothesized that insulin in a dose dependent manner decreases the expression of 
FOXO1 and its target genes affecting decidualization (184).  
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1.5.1.9.3 Chicken ovalbumin upstream promoter transcription factor 2 (COUP-
TF 2) 
COUP-TF 2/ Nuclear receptor subfamily 2, group F, member 2 (NR2F2) is a protein 
encoded by NR2F2 gene. A high expression is seen in stroma and is regulated by 
progesterone-IHH (Indian Hedge Hog) signalling pathway, which is secreted from the 
epithelium. Conditional knockout of COUP-TF2 in mice is shown to be associated with 
infertility and impairment of implantation and decidualization, suggesting a very important 
role in endometrial receptivity. In vivo, epithelial progesterone induces IHH that regulates 
COUPTF2 in the stromal cells, in turn COUPTF2 acts through its downstream target BMP2 
(Bone morphogenetic protein 2) that successfully establishes decidualization and 
implantation (185).  
 
1.5.1.9.4 Heart and neural crest derivatives-expressed protein 2 (HAND2) 
HAND2 is a transcription factor regulated by progesterone and expressed in stromal 
cells. Selective HAND2 knockout mice lack the capability for embryo implantation, 
suggesting an important role in endometrial receptivity and implantation. Progesterone during 
secretory phase induces HAND2 expression in stromal cells, which in turn suppresses the 
production of various fibroblast growth factors (FGFs) that mediate the mitogenic effects of 
estrogens in epithelial cells. With lack of HAND2, as seen with anti progestin treatment, the 
mitogenic effect of FGFs are unopposed leading to proliferation of epithelial cells resulting in 
impaired implantation. Thus HAND2 plays a critical role in the cross talk between stromal-
epithelial cells in order to establish a successful pregnancy by modulating endometrial 
receptivity (186). Epigenome wide methylation studies in endometrial cancers reveal that 
HAND2 is commonly hypermethylated and silenced, thus suggesting HAND2 as a biomarker 
for early detection of endometrial cancer (187).  
 
1.5.1.10 Prostaglandins 
Prostaglandins (PGs) are a group of physiologically active lipid compounds found in 
almost all tissues. PGs contain four members PGD2, PGE2, PGF2α & Prostacyclin (PGI2), 
metabolites of arachidonic acid produced by enzymes cytosolic Phospholipase A2 (cPLA2) 
and cyclooxygenase (COX-1, COX-2). Lack of cPLA2 or COX-2 enzyme leads to several 
implantation defects due to lack of PGs (188).  Most of the PGs are involved in implantation 
process and very little is known about their role in endometrial receptivity. Various roles of 
PGs in endometrium include proliferation of glandular epithelial cells during proliferative 
phase, vascular functions and role in menstruation. Vilella et.al have demonstrated that 
presence of PGE2 and PGF2α synthases in epithelial cells and concentration of these 
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substances in uterine fluid before 24hours of ET serves as potential non-invasive endometrial 
receptivity biomarker (189). 
 
1.5.1.11 Fatty acid binding protein 4 (FABP4) 
  FABP4 is considered as a regulator of proliferation, migration and invasion of 
epithelial cells in endometrium (190). Estrogen upregulates expression of FABP4 and further 
upregulated in combination with progesterone. Significant reduction in the number of 
implanted embryos, decreased deciduas formation with pregnancy loss, inhibition of various 
endometrial receptivity factors are seen with FABP4 inhibition suggesting an important role 
in the regulation of embryo implantation by altering endometrial receptivity (191). 
 
1.5.1.12 micro-RNAs (miRNA/miR) 
miRNA are small non-coding RNA with around 22 nucleotides. Role of miR’s in the 
endometrial receptivity and implantation are explored with the advanced technologies in the 
field of omics and many miR’s such as miR-302a, miR-543, miR-125b are shown to be 
having a role in implantation and endometrial receptivity (192-194). mir-133b has been 
shown play an essential role in endometrial receptivity by reducing SGK1 expression and 
promoting the action of HOXA-10 in successful implantation (195). Lack of miR-451 in 
mice leads to decreased number of embryo implantations by acting on the target gene 
Ankrd46 (196).  
Interestingly, a higher level of miR-645 expression seen in the media of embryos with 
poor pregnancy outcome by IVF treatment and undetectable from media of healthy embryos 
indicates that miRNA are incorporated and used by developing embryos (197). Various 
ongoing studies have demonstrated the significance of different miRNAs and their role in 
embryo development, in early abnormal pregnancies and in implantation failures. In addition 
miRNA are shown to be valuable in predicting the IVF outcome. 
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1.5.2 Diagnosis of endometrial receptivity  
Till date no proven clinical diagnostic test is available for determining the 
endometrial receptivity prior to infertility treatment or to assess the receptive status of 
endometrium before ET in an IVF cycle. Such tests, if available, could help us to identify 
receptive endometrium and also can be useful in personalized embryo transfer in RIF women. 
So far, such a diagnostic test that is clinically validated and universally accepted is not 
available for routine use.  
Conventionally Noyes criteria is used to assess endometrial receptivity in a clinical 
setting. In addition to Noyes criteria, pinopodes, various biochemical markers such as MUC1, 
LIF, HOXA-10, COX-2 etc. are proposed for diagnostic purposes, but none of them have 
been validated and there has been no further success.  
In a natural cycle with sample size of 62 endometrial biopsies, five genes are 
significantly upregulated during the WOI – LAMB3 (laminin beta3), ANGPTL1 
(angiopoietin-like 1), NLF2 (nuclear localized factor 2), MFAP5 (microfibril-associated 
protein 5) and EG-VEGF (endocrine gland-derived vascular endothelial growth factor). 
These are proposed as new biomarkers for receptivity that could be tested in the endometrial 
pathologies and could be used as predictors of IVF outcome (198). 
E-tegrity test, a method of testing endometrial receptivity based on the expression of 
integrin β3 in endometrial biopsies collected during the WOI (199) has been shown to be 
useful in assessing receptivity in fertility disorders such as endometriosis, hydrosalpinx etc. 
Integrin β3 plays a role in receptivity and reduced expression are seen in various endometrial 
pathologies (200).  
Endometrial function test (EFT), a method in which Cyclin E, a cell cycle regulator 
and associated with glandular development, is assessed by immunohistochemical technique 
in the endometrial biopsies. Overexpression of Cyclin E is observed in abnormally 
developing endometrium and in infertile women (201).   
Based on the transcription profile of the endometrium in various phases of pre-
receptive phase of menstrual cycle, a customized genomic tool Endometrial Receptivity 
Array (ERA) comprising of 238 selected genes was introduced for detecting endometrial 
receptivity by next generation sequencing for clinical purposes (202). ERA is considered as 
the most accurate and objective test available today for assessing endometrial receptivity. 
Moreover, ERA displayed a high correlation sensitivity of 0.99758 and specificity of 0.8857 
for endometrial dating, and predicted a specificity of 0.157 and sensitivity of 0.995 for 
pathological classification. A similar approach of using microarray based expression 
consisting of 126 genes, 126 gene model, was explored for the use in endometrial disorders 
(203) and an overlap of 61 genes which were common for both the datasets is observed.   
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Very recently, ER Map (Endometrial Receptivity Map) has been introduced which is 
a new personalized and molecular tool test to detect the uterine receptivity during WOI (204, 
205). In ER Map a panel of 48 genes that are involved in endometrial proliferation and 
immune responses are analyzed by qRT-PCR method. By using discriminant model, ER Map 
classified 100% cases correctly to both fertile and infertile woman. An added advantage of 
ER Map over ERA is that the analysis is performed by qRT-PCR that is easily accessible and 
available in most clinical settings today.  
However, it has to be noted that these techniques are expensive, time consuming and 
lack accuracy and low predictability in diagnosing receptive endometrium. Further, large 
clinical studies have to be done for proving all array based expression test if it is clinically 
useful and validation has to be done to accept them as a diagnostic test for endometrial 
receptivity.  
 
 
1.5.3 Antiprogestins/ Drugs/ Contraceptives to study hormonal 
regulation of endometrial receptivity 
Progesterone is the key steroid hormone driving the endometrial receptivity. Any 
drugs or substances that affect progesterone synthesis or block its action during the luteal 
phase disrupt endometrial receptivity and cause implantation failure and these can also be 
used as important tools in studying endometrial receptivity.  
 
1.5.3.1 Levonorgestrel (LNG) 
LNG is the most widely used drug for emergency contraception (EC) and is effective 
within 72 to 96 hours of unprotected sexual intercourse and works only before pregnancy has 
occurred. It is used as oral contraceptive pills since 1980s and in intrauterine contraception 
since the 1990s and is on the list of WHO’s essential medicine list. LNG dosage for EC is a 
single dose of 1.5mg (or two 0.75mg doses 12hrs apart)(206, 207).  
 
1.5.3.2 Antiprogestins / Selective progesterone receptor modulators (SPRMs) 
Antiprogestins / Antiprogestogens / Progesterone antagonists / Progesterone blockers/ 
Progesterone receptor modulators (PRMs)/ selective PRM (SPRMs) are agents or drugs that 
bind to progesterone receptor and block the biological actions of progesterone. PRMs are 
commonly used for medical abortion and emergency contraception as well as for treating 
uterine pathologies such as uterine fibroids. 
SPRMs are the agents that act on PRs as agonists or antagonist, the actions may vary 
based on tissue i.e. may act as an agonist in one tissue and antagonist in other tissue. SPRMs 
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exert both agonist and antagonist effect on PRs and minimal interactions with other steroidal 
receptors. 
 
1.5.3.2.1 Mifepristone 
Mifepristone (RU-486) is a steroidal anti-progestin and anti-glucocorticoid, to a lesser 
extent anti-androgen and is the first antiprogestin to be discovered. It has a partial agonist in 
action in the absence of progesterone and a competitive PR antagonist in the presence of 
progesterone. It exhibits more than twice of progesterone’s affinity towards PR, more than 
three times that of dexamethasone, ten times that of cortisol towards glucocorticoid receptors, 
and less than one-thirds of that of testosterone towards androgen receptors. Mifepristone does 
not bind to mineralocorticoid and estrogen receptors. The effects of mifepristone 
administration depend on the dosage and the timing during the menstrual cycle; a single high 
pre-ovulatory dose of 200-600 mg inhibits ovulation by affecting follicular development 
whereas a single pre-ovulatory dose of 10 mg delays ovulation by three to four days (208-
210). Immediate post-ovulation (on LH+2) administration of 200 mg mifepristone inhibits 
endometrial development in the secretory phase, thus making the endometrium non receptive 
to the incoming blastocyst, while no effects are seen on ovarian steroid hormone production 
and menstrual cycle. In addition, a once-weekly dose of 5 mg inhibits the endometrial 
maturation without inhibiting ovulation (211, 212). Mifepristone also provides effective 
contraception at a daily doses of 2 to 10mg, by suppressing follicular development, blockage 
of LH surge and by inhibiting ovulation and endometrial receptivity as well as inducing 
amenorrhea. At a daily dose of 0.5mg, a mild delay of endometrial development and a 
reduction in glandular diameter is produced, but no significant changes are seen in the 
menstrual cycle duration, menstrual bleeding, ovulation and ovarian steroid hormone 
secretions and the contraceptive efficacy is insufficient (213-215). Mifepristone is highly 
effective and widely used for medical abortion, cervical ripening prior to surgical abortion, 
treatment of uterine fibroids and has shown to be effective in reducing endometriosis related 
pain (216).  
 
1.5.3.2.2 Ulipristal acetate (UPA) 
UPA/ CDB 2914 is a second generation PRM and is on the list of WHO’s essential 
medicines for EC. UPA has partial agonistic as well as antagonistic effects on PRs. A single 
dose of 30mg within 120 hours of unprotected sexual intercourse is available as an 
emergency contraceptive pill and is approved in Europe since 2009 and by FDA in 2010. In 
addition, a 5mg/day UPA is used as preventive surgical treatment of uterine leiomyoma in 
North America and Europe. Furthermore it has been documented to reduce the size of uterine 
fibroids and control excessive bleeding resulting from fibroids with UPA treatment for 13 
weeks (217-219). Clinical trials demonstrate that UPA is superior to standard LNG-EC in 
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terms of preventing unwanted pregnancies (220-222). UPA, similar to mifepristone, displays 
a dose dependent response on the endometrium with decrease in endometrial thickness and 
down regulation of PRs when exposed to higher doses. Exposure to UPA as a single dosage 
EC i.e. at 30mg showed no significant difference compared with placebo on endometrial 
maturation (223). 
 
 
1.6. Embryo implantation 
Implantation is initiated with the attachment of blastocyst to the receptive 
endometrium, a critical step in establishing a successful pregnancy. Implantation is one of the 
most complex and tightly orchestrated events between embryo and endometrium and the 
mechanism differs in each species.  
 A successful implantation requires endometrium in a receptive phase, regulated 
by steroid hormones, and a viable blastocyst. Trophectoderm layer, outermost layer of 
blastocyst, undergoes a series of maturation leading to a stage known as ‘activated’ that 
includes metabolic changes and the ability to interact with endometrial luminal epithelial cells 
to undergo epithelial-mesenchymal transition for invasion process. The endometrium 
undergoes a series of changes that includes predecidualization, decidualization and secretory 
changes for enabling implantation. 
  
1.6.1 Embryo-endometrial Interactions 
Initial step to facilitate implantation is to build a dialogue between the viable 
blastocyst and receptive endometrium, and this is achieved with the support of growth factors 
and hormones. The prerequisite for implantation is that the blastocyst has to reach a stage of 
activation. Wnt-β-catenin signaling is considered as one of the pathways that helps the 
blastocyst to reach this activation; inactivation of Wnt signaling pathway limits the blastocyst 
competency for implantation (224).  
hCG secreted by the early embryo is one of the earliest embryonic signals that is 
sensed by the receptive endometrium. Clinically detectable levels of hCG are seen even 
before the implantation process starts, whereas mRNA for hCG is detectable at 2 cell 
blastocyst stage (225) and is detected in urine after 7-8 days of conception. In humans and 
other primates, immunization against hCG prevents pregnancy by affecting the embryo 
implantation and it is suggested that immunization against hCG could serve as a 
contraceptive that is reversible (226). Embryonic hCG has both direct paracrine effect on 
endometrium and indirect endocrine actions on corpus luteum to secrete progesterone. This 
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progesterone increases LIF secretion mediated by IL-4 and therefore controls the function of 
endometrium (227). 
Pre-implantation embryo also secrets several cytokines such as TGFα, EGF, IGF 
1&2, PDGF-A, IL-1 system (IL-1α and IL-1β) that take part in embryo-endometrial 
interactions or signalling processes. IL-1 system acting via integrins α4, αV, β3 transforms 
the endometrium and also induces leukocyte differentiation (228). Furthermore, IL-1 induces 
the expression of G-CSF and LIF that bind to preimplantation embryo and activate IGFBP1 
that helps in the embryo invasion. IL-1 stimulates the secretion of MMP-2 & MMP-9 that are 
involved in softening of stromal compartment during implantation (229).  
During the implantation process, hormones such as estrogen and progesterone, 
cytokines, growth factors, chemokines and various other factors such as MUC-1, cell 
adhesion molecules, Leptins, HOX genes, MMPs etc. play an important role in the embryo-
endometrial dialogue, the role of each mentioned factors in implantation has been briefly 
explained in the biomarkers of endometrial receptivity. 
 
1.6.2 Implantation process 
Three phases are involved in the implantation process, apposition, adhesion and 
invasion. During apposition the cells in the blastocyst orient towards the surface of 
endometrium and form a loose connection between blastocyst and endometrium. A dialogue 
between the endometrium and the blastocyst is mediated during apposition by the cytokines- 
IL-1, IL-6, IL-11, LIF and chemokines such as CSF-1 and GM-CSF, which act in a 
bidirectional fashion and help to dock the blastocyst to endometrium. A change in the polarity 
is seen in the endometrial luminal epithelial cells, a key aspect, during the initial apposition 
phase. In an in vitro model, it has been demonstrated that MUC-1 through its ligands for L-
Selectin receptors that are expressed on trophoblast cells mediates the apposition (230). In 
addition, maternal LIF and HOXA-10 also play an important role in the initial attachment 
through their appearance in pinopodes/uterodomes, although exact mechanism is not clearly 
known (231, 232).  
Adhesion ensues the apposition phase and it is in this phase that the embryo attaches 
strongly to the endometrium. Cell adhesion molecules such as integrins mainly mediate this 
phase and trophoblast cells transmigrate the luminal epithelium and penetrate into the 
endometrium. Integrins such as αvβ3, β8, αvβ5, α4β1, αVβ1, Basigin (MMP inducer), 
Osteopontin, Trophinin-Tastin-Bystin complex play a critical role in adhesion by mediating 
cell-to-cell and cell-to-matrix interactions.  
Trophoblast invasion is the final phase of implantation in which the blastocyst 
invades into the decidualized stromal compartment by crossing the anatomical barrier of 
endometrium such as the luminal epithelium layer and basement membrane layer. After 
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successfully invading into the endometrium, the trophoblast cells differentiate into 
syncytiotrophoblast cells and cytotrophoblast cells. The syncytiotrophoblast cells achieve 
further invasion deep into the endometrium beneath the decidual cells, secrete TNFα and 
various matrix metalloproteases such as MMP-9 to lyse the extracellular matrix and make the 
whole embryo to be embedded in the endometrium. Subsequently, the cytotrophoblast cells 
invade the complete endometrium, uterine blood vessels and sometimes to a part of 
myometrium that ultimately initiates the placenta formation.  
 
1.6.3 Challenges in studying endometrial receptivity and implantation 
Implantation is a tightly orchestrated event between the receptive endometrium and 
the embryo and implantation is species specific. Co-ordinated actions of both steroid 
hormones, estrogen and progesterone, is essential for endometrium to prepare for 
implantation. WOI is a very restricted period and varies in different species, such as 24 hours 
in mice and 4-5 days in women, which makes studying WOI difficult.   
In view of ethical and technical constraints, it is difficult to study the mechanism of 
endometrial receptivity and implantation in in vivo and suitable models to study implantation 
are lacking. Much of the information on implantation is derived from animal experiments and 
in vitro cell culture models. However the animal models and in vitro culture models have 
their own limitations – failure to completely translate the information from these models to 
humans in understanding the mechanism of human embryo implantation. 
 Though most of the in vitro cell cultures give clues on implantation, they lack 
cell-to-cell interactions, cell to matrix interactions, limited number of cell phenotypes, and 
lack of paracrine interactions. Most of the in vitro model experiments have concentrated only 
on the initial interactions of embryo/ blastocyst with the epithelial cells. Major constraint with 
the organ explant culture is that they undergo necrosis within a short time in in vitro 
conditions and cannot exactly replicate in vivo mechanism. The lack of polarization of 
epithelial cells in organ culture, which is a pre requisite for implantation, is another major 
limitation.  Similarly, in monolayer co-cultures of stromal or epithelial cells with blastocysts, 
flat and non-polarized cells without intercellular junctions are observed while growing on 
plastic surfaces.  Moreover the cross talk between the stromal compartment and epithelial 
compartment cannot be established. Interestingly, it is demonstrated that the blastocyst can 
attach to any surface covered by epithelial cells of mesodermal origin (233). 
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1.6.4 Ethics and usage of embryos in research 
A question of debate since the invention of IVF is the usage of embryo for research 
purposes. However, the Human embryo research panel of National institute of health (NIH) 
in 1994 proposed the usage of spare embryos for research purposes up to 14 days post 
fertilization (234). The same policy is in effect in Sweden for the purposes of embryo 
research. Extreme care has to be taken to prevent the exploitation of spare embryos for 
therapeutic usage as stem cells are becoming common in routine treatments. Once the expiry 
date for storing of embryos in the freezers is passed, it is advantageous to use the embryos for 
research that could benefit the human beings, rather than destroying them.  
 
1.6.5 Alternatives of embryo and endometrium in reproductive research 
It is always difficult to obtain endometrial biopsies from women and spare embryos 
for research purpose, as using embryos for research is illegal in many countries. In 
reproductive medicine point of view, research in implantation failures and recurrent 
miscarriages leading to infertility is hampered by the availability of human tissue from which 
primary cells can be isolated and limited access to embryos worldwide for experimentations. 
Therefore use of the alternatives such as cell lines that represent endometrium and embryos 
could be an advantage for studying the implantation process and various gynecological 
disorders in vitro. Globally there are over 300 embryonic cell lines representing the 
trophoblast cells that are isolated from the embryos, and two thirds of them are present in just 
five countries – USA, UK, Sweden, France and Spain.  Availability of different cell lines for 
endometrium and trophoblast makes the researchers difficult to select the cell lines for a 
particular function. In this section a brief description of cell lines available as alternatives to 
endometrium and embryo and their particular functions are discussed.  
 
1.6.5.1 Epithelial cell lines 
Most of the endometrial epithelial equivalent cells lines are derived from endometrial 
adenocarcinoma condition such as Ishikawa cells, ECC-1, HEC-1A, HEC-1B and RL-95-2 
(235). Luminal epithelium equivalent cell lines for receptive phase endometrium are EEC-1, 
Ishikawa cells and HES cell lines, whereas HEC-1A is used as substitute for luminal 
epithelium in non-receptive phase endometrium. Ishikawa cells and RL95-2 can be used as 
alternatives of glandular epithelium. For functional studying of adhesion property in 
implantation, HEC-1A is poorly adhesive whereas Ishikawa and RL95-2 are highly adhesive 
to the trophoblast cells. Ishikawa cells have mixed characteristics of both glandular and 
luminar epithelium and are considered a good model for studying endometrial function.  
In general, primary endometrial epithelial cells in in vivo conditions exhibit receptors 
for estrogen, progesterone, androgen, hCG and luteinizing hormone. It is important to choose 
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the cell line with suitable receptors for studying the endocrine signalling pathways in 
implantation or endometrial receptivity. Ishikawa cell lines possess receptors for estrogen, 
progesterone, androgens and luteinizing hormone whereas ECC-1 exhibits receptors for 
estrogen, progesterone and androgens. HEC-1A demonstrates receptors for estrogen and 
progesterone, on the other hand HEC-1B and HES only have estrogen receptors. RL95-2 
cells have estrogen receptors and presence of receptors for progesterone is conflicting. 
 
1.6.5.2 Trophoblast cell lines 
Generally, the trophoblast cells are epithelial in nature and Keratin 7 (KRT7) is 
considered as positive marker of trophoblastic lineage in vivo that include cells such as 
syncytiotrophoblast cells, villous and extravillous cytotrophoblast cells and trophectoderm 
cells. Cell lines that are equivalent to trophoblasts include BeWo, AC1M-88, HTR-8/Svneo, 
JEG3 and JAR cell lines. Of these cell lines, BeWo cells are used for studying 
syncytialization, whereas for studying trophoblast adhesion/migration, AC1M-88 and HTR-
8/Svneo cell lines are employed. For demonstrating invasion mechanism of implantation, 
HTR-8/Svneo, JEG3, BeWo and JAR cell lines are suitable.  
 
1.6.6 Approaches to study endometrial receptivity and implantation 
Ethical constraints limit the ability to study endometrial receptivity and implantation 
in humans. Till date numerous methods were used for studying endometrial receptivity and 
implantation in a quest to promote implantation ultimately resulting in a successful 
pregnancy. An important objective for research in the endometrial receptivity is to improve 
the current ART, since the success rate of ART is still around 30-40%, and in addition, to 
control the fertility by developing novels contraceptives. Advanced omics technologies 
such as sequencing, proteomics, transcriptomics, lipidomics, secretomics, and 
metabolomics etc. have opened up new approaches in the field of biomarker discovery. The 
following approaches available as of now in the field of receptivity discovery are discussed 
briefly. 
 
1.6.6.1 Morphological dating / Histological evaluation of endometrium 
Till today a common technique that is used routinely in the field of endometrial 
physiology and pathology to assess receptivity is the criteria of morphological dating of 
endometrium published by Noyes et al (25). An improved version of morphological dating 
superior and reliable to Noyes criteria is the morphometric analysis, proposed by 
Johannisson in 1982 (26).  17 morphological features are measured in the morphometric 
analysis, 11 features in glands and 6 in stromal cells. The main disadvantage of the 
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morphological method in evaluation of endometrial receptivity is that it is very subjective 
and could vary between the observers. 
  
1.6.6.2 Pathophysiology of endometrium / In vitro fertilization 
One of the best approaches to study endometrial receptivity or implantation is by 
observing the changes in various endometrial pathologies such as endometriosis, RIF, 
hydrosalpinx, and endometrial carcinomas leading to infertility. Studying the molecular 
alterations and biochemical expressions in these pathological conditions provides valuable 
information in understanding the receptivity.  Various factors such as integrin αVβ3, 
ICAM-1, Trophinin, HOXA-10, COUP-TF2, cytokines LIF, IL6 etc. are altered in 
pathophysiology of endometrium. This has led to the discovery and understanding of the 
importance of these factors in endometrial receptivity and implantation.  
  IVF is one of the promising ART techniques so far in treating infertile couples 
and provides a good tool for studying endometrial receptivity and improving embryo 
implantation. Studying the effects of various factors such as hormones, cytokines, ovarian 
stimulations, new synthetic substances and drugs used in treatment that affects endometrial 
receptivity could predict the IVF outcome and vice versa. It is widely known that embryo 
secretes various factors such as cytokines, RNAs, miRNA’s that modulate the endometrium 
towards a receptive phase. In vitro modifications of the embryo culturing medium and 
conditions could help us to understand how these modifications affect the endometrial 
receptivity and implantation.  
 
1.6.6.3 Animal models 
The process of implantation is species specific and is very different in cattle, pigs 
and rodents from human beings. The main difference lies in that the embryo in humans 
appears to have aggressive behavior in invading the decidual tissue and spiral arteries. A 
similar phenomenon of invasion and implantation is seen in non-human primates such as 
rhesus monkeys and baboons. However, in rodents, the mechanisms of embryo 
implantation and uterine receptivity are entirely different in terms of anatomy and 
reproductive physiology such as lack of menstruation. 
 
1.6.6.4 Imaging Technologies / Ultrasonography 
The most conventional, non-invasive way to clinically assess endometrial 
receptivity is by using ultrasonography that measures endometrial thickness, architecture 
and blood flow. Thickness of endometrium varies each day till the day of ovulation under 
the influence of estrogens and not so significant change in thickness is seen during the 
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luteal phase. Endometrial thickness is a question of debate; a meta-analysis of the 
relationship between thickness and IVF outcome concluded that the mean thickness is 
significantly higher in pregnant woman, however the difference in mean thickness of 
<1mm is considered may not be clinically significant (236).  In murines, Liu et al showed 
that ultrasound in combination with molecular imaging with contrast agents to VEGFR2 
may give superior information in assessing endometrial receptivity (237).   
Color Doppler ultrasonography assesses the changes in menstrual cycle progression 
and can quantify the endometrial vascular blood flow. Better assessment of receptivity can 
be done if a three-dimensional ultrasonography approach is used. 
  
1.6.6.5 Omics Approach 
1.6.6.5.1 Genomics / Transcriptomics 
In the recent years, after the completion of human genome project, several 
microarray, transcriptomics, lipidomics, secretomics, proteomics and metabolomics studies 
have been done to identify the important genes and/or proteins that could serve as 
biomarker of endometrial receptivity. In general, omics technology is a high throughput 
experiment where thousands of gene or protein expression can be determined in a given 
condition. One of the challenges of the omics technology is that the data it generates is so 
enormous, which is not used and analyzed to the full extent due to various reasons such as 
lack of proper guidelines in data analysis, difficulty in deriving conclusions, computing 
issues and scarcity of well trained bioinformaticians.  
Several attempts have been made to elucidate gene expression profile of 
progesterone modulated receptive endometrium. With the development of microarrays 
there are at least four studies on human endometrial gene expression during the luteal phase 
(238-240). Although all of these studies used the same technology, the results differ due to 
experimental design and data analysis. The differences include the day of endometrial 
biopsy, phases of the menstrual cycle compared with, genomic variation between patients, 
and pooling or non-pooling the isolated RNA. Despite having a very careful experimental 
design and controlled experimental setup, the results may still vary due to the difference in 
cellular composition, mainly stromal and epithelial cells and the layer of endometrium 
obtained in the biopsy sample. Thus it is of importance to study the compartmentalized 
receptivity gene expression in women in well-timed and defined material in order to 
understand the endometrial receptivity better. Majority of the endometrial receptivity 
biomarkers known today were derived using these same omics approaches.  
Microarrays and transcriptomics based expression profiling has its own limitations 
such as sensitivity and specificity of the probes used in specific platforms, lot of 
background noise and hence is becoming obsolete. Introduction of Next Generation 
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Sequencing (NGS) overcomes the difficulties of microarrays and is proven to be superior to 
the microarrays. NGS has the capability to sequence all the mRNA’s present in the given 
sample and is very sensitive in detecting the genes that are rarely expressed or in low 
expression. Various transcript isoforms and absolute quantification of transcripts can be 
done which cannot be detected by conventional techniques. With the discovery of role of 
small non-coding RNAs, such as miRNA, piRNA, lncRNA etc. in endometrial receptivity, 
NGS serves as the best available sensitive technique today to profile the small RNAs and to 
identify new and novel RNAs that affect receptivity. Some limitations with NGS are that it 
is time consuming, the cost per sample is high, requires high performance computing and 
well-trained bioinformaticians. Because of all these limitations, as of now NGS is available 
only in a few selected laboratories, but is becoming widely popular in routine clinical use to 
diagnose various pathologic conditions. 
 
1.6.6.5.2 Proteomics 
In comparison to genomics, proteomics provides more biological and relevant 
information since it is the end product of genes or RNA or DNA. However, proteomics is 
complicated than genomics because most of the time genome in an organism is constant 
whereas proteome differs from time to time and cell-to-cell, sometimes the mRNA may not 
be translated into protein or less translated due to rapid degradation of mRNA. In routine 
practice, the correlation between genomics and proteomics for the same sample is less, 
which maybe due to the several steps involved in the translation processes, various post 
translational modifications such as glycosylation, phosphorylation, ubiquitination, 
alternative splicing and variation in degradation properties of each protein (241).  
Traditionally proteins can be detected by various immunoassays and the current 
methodologies include 2D-DIGE (fluorescence 2-dimensional differential gel 
electrophoresis), mass spectrometry, reverse-phased protein microarrays and protein 
profiling. Proteomics provides an opportunity to discover the complex biological 
mechanisms involved in endometrial receptivity, fertilization, implantation and pregnancy.  
 
1.6.6.5.3 Secretomics  
Secretomics is a subset of proteomics in which all the secreted proteins from the 
cells or organs such as uterine fluids and embryo secretions are studied. Uterine fluid / 
uterine secretome provides an easy and mild non-invasive approach for sample collection 
and biomarker discovery by proteomic profiling. Uterine fluid proteomics perhaps is a best 
approach for receptivity biomarker discovery as it can be collected by aspiration or lavage 
in the same cycle of embryo transfer without a consequent injury or very minimal injury to 
the endometrium.  
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1.6.6.5.4 Metabolomics /Lipidomics 
Metabolomics is the study and analysis of molecular metabolites in cells and fluids, 
which are the end products of gene expression. Metabolomics or lipidomics employs 
various techniques such as gas chromatography- mass spectrometry (GC-MS), High-
pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), Near 
Infrared spectroscopy (NIR), liquid chromatography-tandem mass spectrometry (LC-
MS/MS) etc. that can detect femtomolar quantities of metabolites with good 
reproducibility.  
 Lipidomics is an emerging, massive study of lipids existing in the cells or 
metabolic pathways. It is well known in the field of endometrial receptivity that lipid 
compounds such as prostaglandins that are derivatives of COX enzymes, lysophosphatidic 
acid (LPA), endocannabinoids and sphingolipids play a key role in receptivity and 
implantation. Lipidomics of endometrium could be studied by analyzing the uterine fluid.  
PGE2 and PGF2α significantly increase in concentration during WOI in the endometrial 
fluid collected at different stages of menstrual cycle (242). 
 
1.6.6.5.5 Epigenomics 
Epigenomics is the study of epigenetic changes on the genetic material of cell i.e. 
epigenome. Important types of epigenetic modifications include DNA methylation and 
histone modifications. Epigenomics could be studied by techniques such as histone 
modification assays, DNA methylations assay (Bisulfite sequencing), ChIP-Chip and ChIP 
seq. It is believed that the cyclical changes that are observed in the endometrium in each 
menstrual cycle are under epigenetic control.  
 
1.6.6.5.6 miRNA/miRs 
miRNAs are small non-coding RNAs that regulate the stability and translation of 
mRNA. Methods to study miRNAs include high throughput miRNA sequencing, miRNA 
arrays, miRNA microarrays, RTPCRs and Locked nucleic acid (LNA) methods. Unlike 
other omics techniques, studying miRNAs has to be extremely careful as it involves 
technical variables such as isolation methods and easy degradation of miRNAs in 
comparison to mRNA due to their length. In addition, ubiquitous presence of RNAses 
makes it difficult to study miRNAs. 
Role of miRNAs in the endometrial receptivity and implantation are explored using 
advanced technologies. The first study on miRNA profiling that is published in 2011, using 
the advantage of deep sequencing and bioinformatics analysis, had revealed the expression 
of 626 miRNAs in natural and stimulated cycles of human endometrium (243).  
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1.6.6.6 Cell/ Tissue cultures  
In vitro cell culture models provide the best and easy approach for studying the 
receptivity as well as in vitro implantation. Greatest advantage of cell cultures is that rather 
than using primary cells from the endometrium, choice of cell lines alternative to the human 
endometrium and embryos are available easily. In addition, cell/tissue cultures provide a 
choice for studying different synthetic compounds of interest, drugs, cytokines and effects 
of various contraceptives.  However, we have to be cautious because implantation and 
many other biological processes differ in vitro and in vivo; moreover the metabolism of 
drugs and compounds differ in vitro and in vivo. Cell/ tissue cultures are further classified 
as explant organ cultures, conventional 2Dimensional models i.e. monolayer cell cultures 
and multilayer cell co-culture models such as 3Dimensional cell co-culture models. 
In organ explant culture, organs or small explants or slices of the organ are dissected 
in vivo during surgeries or in vitro and are maintained for extended times. Advantage with 
organ explant cultures is that it can be used to study pathophysiological mechanisms of the 
cells in vitro, to characterize the histological relationship between various cells in the tissue 
or organ. Perfusion studies on whole uterus obtained by hysterectomy is employed to 
exploit the interactions of trophoblast cells and various test substances added to perfusion 
medium (244). In endometrial explants, the structure of endometrium is maintained in vitro 
and this model helps to analyze the synthesis and secretions of endometrial cells into 
medium to explore the paracrine interactions. Limitations of this model are the differential 
viability of the individual cells and injured or necrotic cells may modify the responses. 
In monolayer cell co-cultures, cells isolated from the tissue or cell line of choice are 
seeded on a plastic surface and the interactions their interactions with embryos or 
trophoblast cell lines are studied. Cells grown in this two dimensional model have flat 
surface and squamous morphology unlike the original cells in endometrium. A simpler 
approach such as growing the cells in the matrigel retains the cell morphology as seen in in 
vivo endometrium (245).  With the recent advances in gene silencing technology, the 
monolayers provide a suitable platform for testing the individual functions and effects of 
the gene. Over the decades, monolayer co-cultures have yielded valuable information on 
receptivity, implantations and interactions between the embryos/trophoblast with the 
endometrial cells and have provided unprecedented opportunities to test the hypotheses by 
manipulating the cells easily in vitro. Advantages of monolayers are that it can be easily 
executed, manipulated and allows study of individual compartments/cells.  Limitations of 
monolayer co-cultures are that it does not mirror the in vivo 3d morphology, relevant 
biological properties are lost due to lack of intercellular communications and interactions 
with extracellular matrix, which makes the translation of evidence from monolayer cultures 
to in vivo difficult. 
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In the field of reproductive medicine, in vitro 3D cell co-culture models of 
endometrium mimics close to in vivo endometrium in terms of anatomy and functional 
aspects and interaction of embryo with the endometrium close to nature (66, 246). In this 
3D endometrial model endometrial cells (epithelial and stromal cells) are isolated and 
grown in layers mimicking the organization of in vivo endometrium and the embryo 
interactions can be studied in this model similar to in vivo conditions. Few limitations as 
seen with other cell culture models are also present in this model such as lack of immune 
cells that play a pivotal role in pregnancy and inability to study trophoblast invasion 
mechanism etc. and further research into this model can fine tune and overcome these 
limitations. 
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2. Aims of the thesis 
 
The overall aim of this thesis is to expand the understanding of various factors that are 
affecting the endometrial receptivity and the human implantation process, thus helping in the 
treatment of infertility and in regulation of the fertility. The specific aims of the thesis are as 
follows: 
 
1. To explore the role of Leukemia Inhibitory Factor in human embryo implantation and 
its viability by inhibiting the action of LIF using Poly-ethylene glycated leukemia 
inhibitory factor antagonist in an in vitro endometrial 3D cell co-culture model. 
 
2. To explore the actions of ulipristal acetate, in the dosage used for emergency 
contraception, on endometrial receptivity and human embryo implantation process in 
an in vitro endometrial 3D cell co-culture model.  
 
3. To explore the effects of two different low doses of mifepristone (0.5 µM and 0.05 
µM) during the receptive phase of endometrium on endometrial receptivity and 
human embryo implantation process in an in vitro endometrial 3D cell co-culture 
model. 
 
4. To identify the differential transcriptomic signatures regulated by progesterone in the 
epithelial and stromal compartment of the receptive endometrium of proven fertile 
woman using laser capture micro dissection. 
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3. Materials & Methods 
Detailed description for materials and methods for each study is given in the 
corresponding original articles (Paper 1- Paper IV). However, an overview of materials and 
methods of all the studies will be provided here in the following sections.  
 
3.1 Materials  
3.1.1 Ethical permits 
The Regional ethical review board, Stockholm, approved all the studies. We used 
cryopreserved supernumerary blastocysts obtained from the IVF clinic (Fertilitetscentrum, 
Stockholm, Sweden). As per the local regulations and existing laws, only embryos 
cryopreserved for more than five years, which are otherwise to be discarded or patients who 
are no longer interested in the embryo cryopreservation after conceiving and were willing to 
donate for research purpose were used in these studies. Written informed consent was 
obtained from all the couples and subjects.  
 
3.1.2 Subjects 
In all the studies, healthy proven fertile woman (should have had at least one 
spontaneous conception), aged 22-40 years with regular menstrual cycles volunteered to 
participate in the studies. Main inclusion criteria for the recruitment was that, none of the 
subjects have not used any hormonal therapy or intrauterine devices (IUDs) for contraception 
for three months prior to the study and were free from any gynecological pathologies. Barrier 
contraception was recommended, if at all the subjects were not sterilized.  
 
3.1.3 Endometrial biopsies 
The endometrial biopsies were obtained from the upper part of uterine fundus using 
pipelle aspirator (Prodimed, France). All subjects self examined for LH peak from cycle day 
10 to LH+2 twice daily in the urine sample using LH self test urine strips (Clearplan, Searle 
Unipath Ltd., Bedford, UK). In paper 1, timed endometrial biopsies from fertile donors were 
obtained at LH+4 (n = 20), in paper 2&3 twenty biopsies on LH+4 were utilized. In paper 4, 
nine endometrial biopsies were obtained on day LH+2 and LH+6/7 for transcriptomics study 
using microarray. 27 endometrial biopsies, nine biopsies each during proliferative, mid and 
late secretory phase for immunohistochemical study and 30 biopsies on LH+4 day is 
collected for in vitro 3D cell culture study. In addition for determining the protein expression 
of ENPP3, 6 biopsies were obtained from control and treatment cycle (200mgms of 
mifepristone on LH+2) on day LH+6 to LH+9. 
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3.1.4 Uterine fluid 
Uterine fluid was collected from the fertile woman with or without treatment (single 
dose of 200mg mifepristone on LH+2) and uterine fluid was collected on day LH+7 (Study 
4). Another set of uterine fluid samples were collected for proteomic analysis during the early 
secretory phase LH+2 and mid secretory phase LH+8. In either sets, 2ml of water for 
injection grade (for Western blot analysis in paper 4) or PBS (for mass spectrometry, in paper 
4) was used to collect the uterine fluid along with the uterine lavage from the uterine cavity 
using a modified feeding catheter (Nutrisafe 2, Fr-L.75cm, France).  Of the 2ml injected, 
around 1ml was sucked back with the help of syringe and the fluid was centrifuged at 200g 
for 10min to remove contaminating blood cells and cell debris.  
 
3.1.5 Embryos/Blastocysts 
Supernumerary embryos/ blastocysts of clinically usable quality with minimum grade 
3BB as per Gardner and Schoolcraft classification were used in all the studies. A total of 69 
blastocysts were collected, 51 embryos survived the thawing and were used in studies as 
mentioned in Paper 1. In paper 2 a total of 20 embryos, 10 in the control group and another 
10 in UPA treated group were used. In paper 3, a total of 28 embryos were used, 10 each in 
control, 0.05µM and 8 in 0.5µM mifepristone groups. For paper 4, a total of 18 blastocysts 
were utilized, of them 10 were used in control cultures and 8 were used in the treatment 
group. 
 
 3.1.6 In vitro treatment protocol 
A modified alpha medium, herein termed as control medium was used for all the 
studies using in vitro 3D cell cultures involving embryos. All the control cultures had equal 
quantity of vehicle/solvent that was used for resuspension of drug. The following treatment 
protocols were employed for in vitro co-culture models,  
Paper 1: 10 embryos were exposed to control medium with vehicle alone, 5 are exposed to 
control medium with vehicle plus polyethylene glycol (13µM, equimolar to PEG in PEGLA) 
(PEG) and 10 are subjected to exposure of 800pg/ml PEGLA, a LIF antagonist. A similar 
protocol was used for examining the direct effects of PEGLA on human embryos, 13 
blastocysts per each group of control and PEGLA treated for AKT/Caspase-3 study.  
Paper 2: The 3D cell cultures are exposed to UPA in a dose of 200ng/ml concentration that is 
equivalent to conventional dose of UPA used in emergency contraception (30mg orally).  
Paper 3: Embryo endometrial co-cultures are exposed to 0.5µM Mifepristone (n=8) and 
0.05µM Mifepristone (n=10) dosage in modified alpha medium. 
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Paper 4: A mifepristone dosage of 0.5µM is used for the embryo co-cultures to demonstrate 
the regulation of ENPP3 expression by progesterone.  
 
3.2 Methods 
3.2.1 Endometrial cell isolation 
The endometrial biopsies collected in Ham F10 + 20% FBS + Penicillin/Streptomycin 
were processed immediately for individual endometrial cell isolation. Briefly, biopsy was 
minced into 1x1mm pieces with scalpel in Ham F10 medium and centrifuged, discarded the 
supernatant and Pancreatin-Trypsin Solution (0.5gms/10ml trypsin) was added and incubated 
at 40C on ice with gentle agitation, every five minutes, followed by incubation at room 
temperature (RT) for 10min and centrifuged. The supernatant was discarded and incubated 
with 5 ml FBS to prevent the digestion by remaining trypsin for 10 min and centrifuged. The 
supernatant is discarded and incubated with 5ml of warm collagenase type 4 solution plus 
DNAse mixture and incubated for 30 min at 370C and centrifuged and supernatant was 
discarded. The cell mixture was sieved in Ham F10 through a 40µ cell strainer, the epithelial 
glands were retained in the strainer and stromal cells were collected from the filtrate. The 
epithelial glands were washed, collected and incubated with collagenase type 3 solution with 
DNAse mixture in PBS for 30 min at 370C and centrifuged and resuspended in fresh Ham 
F10 media. The mixture was filtered through a 40µ cell strainer and epithelial cells were 
collected from the filtrate. Stromal and epithelial cells were resuspended in freezing mixture 
and the cryovials were stored in Mr. Frosty cryobox, stored at  -800C for 24 hours and then 
shifted to liquid nitrogen and stored till further usage. 
 
3.2.2 3Dimensional Endometrial Cell Co-Cultures  
Endometrial 3D cell cultures were constructed with minor modifications as described 
earlier (66, 247). Briefly, the collagen gel type 1 (Purecol 3mg/ml, Advanced Biomatrix, 
USA) was mixed with 10X PBS and pH adjusted to 7.4 with NaOH and 175µl of this gel was 
pipetted into the Millipore cell culture insert, the gel was polymerized by incubating at 370C 
for 30 min. Stromal cells (2 million/ml) were thawed and mixed with 200µl of the gel, 
overlaid on the solidified collagen gel in the insert and incubated at 370C for 30min. After the 
stromal gel solidifies, a layer of thin basement membrane extract (100µg/ml) (Matrigel, 
Belgium) is coated on the top of the stromal gel. Epithelial cells (0.2million/ml) were thawed 
and mixed with modified alpha medium and pipetted onto the matrigel coating and incubated 
for five days at 370C in 5% CO2 incubator, medium change is given for every 2 days and 
once the epithelial cells reach the confluency the desired treatment is started and co cultured 
with blastocysts for five days.  
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3.2.3 Immunohistochemistry (IHC) 
All IHC kits were obtained from Biocare Medical, Concord, CA. The paraffin 
sections were deparaffinized and antigen retrieval was done in DIVA decloaker solution in 
2100-retriever autoclave followed by washed in hot rinse solution. Endogenous peroxidase 
activity was inhibited by treating with undiluted peroxidazed for 5 min in darkness and 
treated with background sniper for 10 min to reduce the non-specific background during the 
staining. Following, the sections were incubated with the primary antibodies for an hour in 
RT or 40C overnight. Then sections were washed with TBS and incubated with MACH3 
Probe (Mouse/Rabbit) corresponding to the species of primary antibody used. Afterwards, the 
sections were washed with TBS several times and incubated with MACH3 HRP polymer 
followed by incubation with betazoid DAB chromogen kit and counterstained with 
hematoxylin solution for a minute. The slides were dehydrated using series of increasing 
concentration of ethanol, washed in xylene and mounted using Pertex.  The identification of 
the slides were blinded and semi-quantitative analysis was performed using IRS scoring 
method (248), separately for the glandular and stromal compartments, by two independent 
observers. The scoring was performed as follows: IRS (Immuno Reactive Score) = SI 
(staining intensity) X PP (percentage of positive stained cells) If there was a disparity of more 
than 25% of the score, a third independent observer analyzed the slides and the average score 
of the two closest results was taken for further analysis. 
 
3.2.4 Immunofluorescence and Immunocytochemistry (Paper 1) 
Immunofluorescence and immunocytochemistry were employed in the paper 1. 
Immunofluorescence was performed for visualizing the expression of cell survival factor 
Phospho AKT in the blastocysts treated with PEGLA and immunocytochemistry was 
performed on the embryos treated with PEGLA or controls for the apoptosis marker cleaved 
caspase 3. In briefly, the fixed blastocysts were permeabilized for 30 min in 0.25% Triton-X 
100 and incubated in 0.1% bovine serum albumin (BSA) blocking solution. The sections 
were incubated with anti-cleaved caspase 3 antibody in immunocytochemistry and with anti-
phospho-AKT antibody in immunofluorescence for overnight. After incubation, the sections 
are washed thrice in blocking solution comprising of 50mg BSA, 5 µl Tween 20 in 50ml 
PBS. Secondary antibody (Alexa flour 488) incubation is ensued washing step for one hour at 
room temperature in darkness followed by washing thrice in blocking solution and mounting 
of embryos is done in vecta shield and observed under Ziess Axioskop microscope. For each 
experiment negative controls are also performed substituting the primary antibody with 
isotype matched IgG with same concentration as used for primary antibody. 
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3.2.5 Laser capture micro dissection (LCMD) (Paper 4) 
For LCMD, sections of 10 µm were prepared from the frozen endometrial biopsies 
using a cryotome and the sections were fixed on UV treated membrane slides using 70% 
ethanol at -200C for 30min. The sections were stained with HistogeneTM staining solution 
(Applied Biosystems) and around 200 epithelial and stromal cells were dissected out using 
PALM laser-Microbeam system (355-nm diode laser) with the assistance of PALM 
Robosoftware (Carl Zeiss, Germany) as per the manufacturer protocol. All steps were 
performed strictly in RNAse free environment, in addition a separate set of LCMD was 
performed and RNA extracted for real time PCR analysis apart for microarray analysis.  
 
3.2.6 Microarray and microarray analysis (Paper 4) 
Microarray for LCMD epithelial and stromal cells was performed at core facility 
(Bioinformatics and expression analysis in Karolinska Institutet). NUGEN Ovation Pico 
WTA system  (Nugen Technologies) was used for RNA amplification. The amplified RNA 
was used to generate sense target of cDNA using NUGEN WT-Ovation Exon module version 
1.0. NUGEN encore biotin module was used for the purpose of fragmentation, biotin labeling 
and ST cDNA preparation and microarray is performed on Affymetrix GeneChip platform 
(Human gene 1.0 ST array) that corresponds to 28,829 annotated genes.  
 The signals from CEL files of microarray were converted using Affymetrix 
expression console and the following particulars were used: PLIER (Probe Logarithmic 
Intensity Error Estimation) for summarization algorithm with PM-GCBG background 
correction and quantile sketch method for normalization procedure. The data was thoroughly 
checked for quality control and interfering outliers using R Software and differential 
expression analysis was performed using SAM (Significance Analysis of Microarrays) and 
MeV software (part of TM4 microarray suite). The differentially expressed genes obtained 
from the microarray analysis were further analyzed for functional and canonical pathways 
using IPA (Ingenuity Pathway Analysis) software (Qiagen).  
 
3.2.7 RNA extraction and real time PCR 
In paper1 RNA extraction was done from the paraffin sections of endometrial 
constructs and from the blastocysts by using the Picopure RNA isolation kit (Arcturus, USA) 
as per manufacturers protocol. In paper 2 & 3 the endometrial constructs after termination 
were lysed in 1ml of Trizol reagent followed by extraction of RNA, similarly in paper 4 the 
laser capture micro dissected endometrial epithelial and stromal cells were lysed in lysis 
buffer and extraction of RNA was done using picopure RNA isolation kit (Arcturus, USA). 
All samples were DNAse treated to remove contaminating genomic DNA and the RNA 
quality control was assessed on Biorad Experion Highsens automated electrophoresis system 
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or on Agilent 2100 bioanalyzer. Complimentary DNA (cDNA) synthesis is done from the 
extracted RNA by VILO superscript kit (Invitrogen) as per the manufacturers protocols. The 
cDNA obtained was used for RT-PCR using Step One Plus machine (Applied Biosystems) 
with VIC/FAM as reporting dyes. ΔΔCt comparative method was used for analyzing the 
RTPCR results. The list of primers and genes used for RTPCR are mentioned in the original 
articles.  
 
3.2.8 Western Blot (Paper 4) 
ENPP3 protein expression in the tissues and uterine fluid as mentioned in the paper 4 
were analyzed by a completely automated western blot system (Protein Simple, USA) and 
analysis was done with its associated Compass software as per the manufacturers 
instructions. Initial protein quantification was done using standard BCA method and 2µg of 
protein either from the uterine fluid samples or from tissue lysates was used in the assay. An 
incubation of 45 min for primary antibody and 60 min for secondary antibody was performed 
and streptavidin and luminal peroxide fluorescence detection method was used. Anti-ENPP3 
antibody (Sigma Lifesciences, HPA043772) is used in a 1:50 dilution. 
 
3.2.9 Deglycosylation (Paper 4) 
In order to confirm the expression of ENPP3 in glycosylated form, the uterine fluid 
samples and endometrial tissue lysates were treated with 1 µl/sample of PNGase-F, an 
enzyme that digest the glycosylated moiety, the efficiency of PNGase-F or Deglycosylation is 
assessed by automated western blot as mentioned under western blot. 
 
3.2.10 Nano-ESI-LC/MS/MS (Paper 4) 
The mass spectrometry (MS) for proteomic analysis in the uterine fluids was 
performed using nano-ESI-LC/MS/MS (Thermo fisher scientific) at University of Tartu, 
Estonia. SDS-PAGE was used to separate the uterine fluid into six fractions based on the 
molecular weight. After fractionation the proteins were reduced and alkylated and in-gel 
digested using trypsin and analyzed by MS using electro spray ionization technique for 
2hours phased gradient method. The MS data was quantified with MaxQuant software 
(UniprotKB reference human proteome database) and MaxLFQ algorithm is used for the 
normalization of label free data.  
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3.2.11 Statistical Analysis  
Non-parametric Mann-Whitney test was performed for analyzing 
immunohistochemistry data elsewhere in this thesis. Fisher’s exact test is used to calculate 
the statistical significance for embryo implantation rates in the 3D cell culture models in 
paper 2, 3 and 4 whereas Chi-square test is employed for paper 1 for embryo attachment rate. 
Paired T Test and SAM methods were used for analyzing the microarray data and paired or 
unpaired t test is used for analysis of mass spectrometry data in paper 4. Kruskal Wallis test 
was performed for the statistics of age of patient, embryo vitrification day and blastocyst 
grading. For RTPCR data, based on the assumptions of normality and variance either 
parametric T-Test or non-parametric Mann-Whitney test is employed. All statistical tests 
were performed using Statistica 10 (Statsoft Inc.) and XLStat 2015 (Addinsoft) and a value 
<0.05 is considered statistically significant. 
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4. Results & Discussion 
 
4.1 Paper 1: In this paper we demonstrated the role of LIF in human embryo implantation 
using in vitro 3D endometrial cell culture, the role of LIF in blastocyst viability by inhibiting 
the action of LIF using LIF antagonist PEGLA.  
 
4.1.1 Results  
None of the 10 embryos in PEGLA treated group were attached to the endometrial 
constructs, whereas 7 and 6 were attached in the control + vehicle and control + PEG groups 
respectively with statistical significance of p < 0.01 (chi-square test). No statistical 
significance is observed between the two control groups (p = 0.639). No statistical 
significance is seen between the age of patients (p = 0.148), embryo freezing day (p >0.05) 
and blastocyst grade (p = 0.965) used in the study.  
 
Figure 3: Effect of PEGLA and PEG alone on blastocyst attachment  
 
 
 
 
 
 
 Immunohistochemical analysis demonstrated a reduced expression of LIF and 
gp130 in epithelial cells of the PEGLA treated group in comparison to controls (p=<0.05). A 
similar observation was seen for LIF in RTPCR with 4.3 fold down regulation in PEGLA 
group (p = 0.03). However, gp130 expression by IHC in the stromal cells of PEGLA group 
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showed no significant difference from the control group. LIFR expression levels did not vary 
in either of the groups in stromal and epithelial cells. RTPCR analysis revealed no 
statistically significant differences in LIFR and gp130 expression between the control and 
PEGLA treated group. 
 In vitro, direct culture of embryos with PEGLA led to significant reduction in 
number of embryos hatched and blastocyst expansions (p < 0.01), undetectable levels of cell 
survival factor phopsho-AKT1 and an increased activity of apoptosis marker cleaved caspase 
3 by immunofluorescence.  
 
4.1.2 Discussion 
To our knowledge, for first time we demonstrated the role of LIF in human embryo 
implantation by 3D endometrial co-culture model that mimics the in vivo endometrium to the 
closest. Inhibition of LIF by stable LIF inhibitor, PEGLA, inhibits embryo attachment to the 
cultures clarifying the role of LIF in human embryo implantation, in vitro. In addition, in this 
study we have demonstrated that LIF is required in optimal levels probably <10pg/ml in the 
endometrium of receptive stage for a successful embryo implantation.  
It is well known that LIF expression is seen in the trophectoderm cells of the embryo 
and LIFR expression throughout the inner cell mass of the blastocyst suggesting an important 
role of LIF in development of blastocyst. This led us to study the direct role of LIF in the 
blastocyst development and here, we elucidated that LIF is essential for blastocyst 
development, expansion and hatching as PEGLA treatment abolished all the mentioned 
processes mediated by LIF. Furthermore, we also proved that LIF is critical for embryo 
survival by maintaining a balance between apoptosis factors and cell survival factors, as 
inhibition of LIF increased the activity of apoptosis marker cleaved caspase 3 and a down 
regulation of cell survival factor phospho-AKT 1. 
 A common approach to study the role of cytokines in clinical use is by using 
stable and potent inhibitor with a longer half-life and efficacy (249), therefore we used LIF 
inhibitor conjugated to PEG which has increased half-life and efficacy as it is already 
demonstrated that non-PEGylated LIF antagonist has a short serum half life of around 10-
30min (250). Moreover, in vivo PEGLA administration has been shown to affect endometrial 
receptivity and decrease implantation when administered vaginally.  In order to rule out the 
adverse effects of PEG, if any, we demonstrated, in another control group treated with PEG, 
had no difference in the blastocyst attachment rate compared with controls with vehicle. 
Similarly, in vivo PEG administration in mice models had no effect on the implantation (251). 
 Experimental evidences indicate that PEGLA blocks LIF activated STAT3 
phosphorylation in the endometrial epithelium during the pre implantation period (252). A 
similar observation is seen in our study – a reduced expression of LIF and its signal 
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transductor gp130 in the epithelial cells as visualized by IHC and RTPCR analysis for LIF 
confirming the actions of PEGLA on LIF signal transduction at endometrial level. Earlier 
studies conducted in different animals species have tried to explore the possibility of 
developing non-hormonal contraceptives targeting LIF (253), and the results from this study 
indicate a strong possibility for the development of non-hormonal contraceptives targeting 
endometrial LIF. 
 
4.2 Paper 2: In this study we demonstrated the effect of UPA used for emergency 
contraception (30mg) on endometrial receptivity and embryo attachment in a 3D endometrial 
co-culture model.  
 
4.2.1 Results 
In the UPA treatment (200ng/ml) group 50% of the blastocysts attached to the 
constructs whereas in the control group 70% attached to the constructs (Figure 2). No 
statistically significant difference is seen between the groups in blastocyst attachment rate 
(fishers exact test, p=0.650).  
 
Figure 4: Blastocyst attachment rate in control and treatment groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* p value < 0.05  
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In order to observe the effects of UPA on embryo implantation and endometrial 
receptivity, seventeen related genes were analyzed from the constructs with RTPCR (Table 
2). The genes studied include cytokines, cell adhesion molecules, transcription factors, 
growth factors, decidualization markers etc. Of the 17 genes analyzed by RTPCR, six of 
them, namely HAND2, OPN, HBEGF, CALCR, FGF2 and IL6, were differentially expressed 
between the groups and were statistically significant with the treatment. HAND2, OPN, 
FGF2 and CALCR were significantly downregulated, whereas HBEGF and IL6 were 
significantly upregulated in the treatment group. Progesterone receptor (PGR) expression was 
seen in all the samples irrespective of treatment, but significant down regulation of PGR was 
seen in UPA treated group (p<0.001). No statistical significance in PGR expression was seen 
between the embryo attached and non-attached groups in the treatment group.  
 
Table 2: Gene expression levels of selected endometrial receptivity markers, embryo 
implantation process and decidualization analyzed by RTPCR after exposure to UPA 200ng/ml 
(study 2) and two low doses of mifepristone (0.5µM and 0.05µM) (study 3).  
* p value < 0.05  
Gene 
 UPA 
200ng/ml 
Fold change 
 UPA 
200ng/ml 
p-value 
Mifepristone 
0.5µM       
Fold change 
Mifepristone 
0.5µM            
p-value 
Mifepristone 
0.05µM      
Fold change 
Mifepristone 
0.05µM         
p-value 
Transcription factors 
HAND2 -2.74 0.003* -2.28 0.0040* -2.32 0.004* 
HOXA10 -1.07 0.307 -7.94 0.0003* -7.41 0.003* 
FOXO-1 -2.01 0.055 -4.54 0.0001* -7.56 0.0001* 
COUP-TF2 -2.29 0.306 7.88 0.0001* 6.75 0.008* 
Cytokines 
LIF -1.39 0.107 -2.15 0.005* -2.13 0.005* 
IL-6 2.63 0.025* 1.19 0.165 3.51 0.003* 
IL1A 1.26 0.065 -1.15 0.472 -1.56 0.028* 
Growth factors 
FGF2 -2.06 0.023* -12.04 0.0001* -13.21 0.0001* 
CSF-1 -1.09 0.48 1.36 0.088 1.06 0.999 
HBEGF 2.48 0.009* 1.03 0.670 0.6 0.154 
VEGFA 1.09 0.596 -1.29 0.219 -3.77 0.0001* 
Decidualization factors 
PRL -1.47 0.427 -8.79 0.0001* -18.68 0.0001* 
IGFBP1 -1.34 0.653 -2.29 0.0002* -2.38 0.003* 
Receptors 
OPN -3.89 0.004* -2.96 0.005* -10.12 0.0001* 
PGR -4.89 0.001* -2.14 0.001* -1.85 0.01* 
MUC1 -1.44 0.391 1.7 0.154 1.43 0.428 
CALCR -2.52 0.016* - - - - 
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4.2.2 Discussion 
 UPA is a second generation SPRM with both agonistic and antagonistic actions 
on PRs. UPA in a single dose of 30 mg is used as emergency contraception, however the 
exact mechanism of action of UPA on the receptive endometrium and implantation is not 
clearly known. In this study, we demonstrated for the first time the action of UPA used as 
emergency contraceptive, on blastocyst attachment rate and effects on various endometrial 
receptivity markers in vitro using a 3D endometrial model. This dose of UPA did not affect 
the blastocyst attachment significantly in comparison to the control group and most of the 
receptivity markers were unaffected, as demonstrated in this study.  
 Technically and ethically it is impossible to study the effects of SPRMs or any 
anti progestins in vivo and most of the available data of UPA on implantations has been 
obtained from animal models and non-human primates, which have contributed valuable 
information in understanding the mechanism of anti progestins (254, 255).  The 3D cell 
culture model that we employed here has been proven to be useful in understanding the 
mechanism of actions of various antiprogestins, cytokines on implantation process (113, 256, 
257) and is the closest available in vitro model of endometrium. The mean serum 
concentration of UPA observed after a dosage of 30 mg orally is 176 ± 89ng/ml (258) and in 
this study we used a continuous dosage of 200 ng/ml during the culture that is slightly more 
than mean serum concentration. However it has to be noted that steroid hormone 
concentrations are seen in higher levels in the endometrial tissue rather than the serum, 
though we do not know in vivo levels of UPA at endometrial level when used at the above 
dose. 
A quick search on endometrial receptivity and implantation markers would yield 
numerous biomarkers such as cytokines, CAMS, transcription factors and so on, and with the 
advancing technologies this number is increasing exponentially but none of them has been 
proved to be the best receptivity marker. Previous studies conducted to explore the efficacy of 
UPA in endometrial receptivity were investigated for a limited number of markers (259), 
hence, in this study we explored the effect of UPA on a large number of receptivity markers 
belonging to different classes and selected 17 important markers that are well reviewed in the 
literature including the decidualization markers.  
In the current study we found that most of the genes that are important and vital for 
implantation such as cytokines LIF, IL1A, growth factors CSF-1, transcription factors 
COUP-TF2, FOXO1, HOXA10, enzyme SGK1, angiogenesis factor VEGFA and MUC1 are 
unaltered in the endometrial constructs exposed to UPA. Several studies have demonstrated 
the importance of LIF and our study using 3D culture model showed that inhibiting LIF in 
cultures prevented implantation and embryo viability (257), as was also with FOXO1, 
HOXA-10 and COUP-TF2. In the present study it is evident that UPA did not have any 
significant effect on the above-mentioned factors despite the pharmacological dose used in 
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the culture. Decidualization is an important physiological phenomenon triggered by the 
implantation event and Prolactin and IGFBP1 are considered important biomarkers of 
decidualization and lack of decidualization has been linked to implantation and pregnancy 
failure (260). In the event of implantation, expression levels of PRL and IGFBP1 are 
increased by many fold, in contrast we observed no significant changes in the expression 
levels of this markers with UPA treatment in vitro. This could be due to failure of trophoblast 
cells to invade the 3D constructs unlike in the in vivo conditions, a limitation of this 3D 
model in the study of invasion mechanism. Further fine-tuning of this model may overcome 
this limitation.  
In this study we found six genes, IL6, HBEGF, HAND2, FGF2, OPN and CALCR 
that are differentially regulated with UPA exposure. IL6 and HBEGF were significantly 
upregulated and the rest four were downregulated. Reports indicate that with the trophoblast 
conditioned medium an increase in IL6 expression (261) is seen, the expression of IL6 is in 
line with the mentioned reports. HAND2 exerts its action of anti proliferation on epithelial 
cells through the suppression of FGF2 signalling (186). Increased expression of HAND2, 
FGF2, HBEGF, OPN and CALCR are seen in the preimplantation phase endometrium. This 
increased expression levels observed with the UPA treatment could be attributed to the 
agonist action of UPA towards the progesterone receptors. Moreover, receptivity is regulated 
by a cascade of mechanisms of several factors but not by a single marker. However, UPA is 
effective in preventing pregnancies if administered before the ovulation by delaying follicular 
maturation. 
Logically and arguably, implantation itself could be the best marker for the 
receptiveness of endometrium. Therefore, from the findings we presume that UPA does not 
affect the receptivity of endometrium and ultimately implantation, as was evident in this 
study. 
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4.3 Paper 3: In this study, we explored the effects of two low doses of mifepristone on 
endometrial receptivity and blastocyst attachment using an in vitro 3D endometrial co-culture 
model. 
 
4.3.1 Results 
In control group, 70% blastocysts were attached to the endometrial constructs, in 
0.05µM group, 40% were attached whereas in the 0.5µM group none of the blastocysts 
attached to the constructs (fishers exact p= 0.004) (Figure 2). However, no statistical 
significance was seen between the control and 0.05µM mifepristone group with the embryo 
attachment rate (fishers exact p=0.369). 
To explore the effect of two low doses of mifepristone on endometrial receptivity and 
implantation, 16 genes that are considered to be biomarkers of endometrial receptivity and 
implantation were analyzed in the endometrial constructs by RTPCR (Table 2). In both the 
treatment groups PGR expression was measured and was found to be significantly 
downregulated by 2.14 fold (p = 0.001) in 0.05µM and 1.85 folds (p=0.01) in 0.5µM 
mifepristone group. Of the tested 16 markers by RTPCR nine of them were differentially 
expressed in both the treatment groups, whereas IL6, IL1A and VEGFA were differentially 
expressed in only 0.5µM mifepristone treated group in comparison to control group. 
 
4.3.2 Discussion 
We have previously demonstrated the effect of 10µM mifepristone on endometrial 
receptivity and embryo attachment (113) and in this study we explored the effects of two low 
doses of mifepristone on endometrial receptivity and subsequent blastocyst implantation in a 
well-established and proven endometrial 3D cell co-culture model. For the first time, we 
show that exposure of receptive endometrium to a 0.5µM dose of mifepristone alters the 
molecular signature of the receptive endometrium and inhibits implantation.  
In vivo, the endometrium is receptive during the WOI that spans between LH+7 to 
LH+11 under the influence of progesterone hormone. In order to mimic this situation in vitro, 
the stromal and epithelial cells in the endometrial construct were primed with progesterone to 
simulate in vivo condition as closely as possibly we can. Moreover, we have shown that the in 
vitro model that is employed is suitable for studying the initial phase of the implantation i.e. 
adhesion phase.  
Mifepristone in the oral dose of 5mg has been shown to inhibit ovulation and a daily 
administration of 5 mg mifepristone in treatment of leiomyoma causes marked endometrial 
changes (214, 215, 262).  Mifepristone dosage of 0.5 µM used in the current in vitro study 
represents the in vivo concentration attained in the uterine tissue after a single 5 mg oral dose. 
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Interestingly, in a clinical trial of mifepristone (5mg/week) only as the contraceptive agent, a 
reduced fertility was observed, but did not completely prevent the pregnancy (263). Here we 
wanted to identify a low dose of mifepristone that could inhibit implantation. Since 
pronounced changes were observed at the molecular and functional levels with 0.5µM 
treatment for 5 days, we reduced the dosage to one tenth of 0.5µM i.e. 0.05µM. An ideal 
study to derive the dose response effect of mifepristone would be to use graded 
concentrations with a series of experiments. However due to limitation of availability of 
blastocysts and endometrial biopsies we tested only two low doses of mifepristone. 
Of all the receptivity markers analyzed from the endometrial constructs no 
statistically significant difference was observed between 0.5µM and 0.05µM treatment 
groups, except for IL6. We hypothesize that this behavior of IL6 as, an inflammatory trigger 
associated with the cells to repair the response due to the withdrawal of progesterone action 
by a low dose of 0.05µM mifepristone, since no change in the embryo attachment rate was 
seen in comparison to control group. Moreover, it has been shown that mifepristone per se 
has no adverse effects on the embryo in a primate model (264), therefore we conclude that 
findings of the present study are not the direct effect of mifepristone on blastocyst but are due 
to the effects on endometrium.  
 
4.4. Paper 4: In this study we explored the gene expression changes in the stromal and 
epithelial compartment regulated by progesterone in receptive endometrium using laser 
capture micro dissection. We propose that glycosylated ENPP3/cd203c, a progesterone-
regulated factor, has the potential to be used as a non-invasive test for diagnosing endometrial 
receptivity. 
 
4.4.1 Results 
In this study, LCMD of epithelial and stromal cells followed by RNA extraction 
yielded a minimum of 500pg RNA. Microarray data analysis revealed 47 genes differentially 
regulated with antiprogestin mifepristone treatment, 32 up and 15 down regulated, in the 
epithelial compartment. In the stromal compartments 85 genes were differentially expressed, 
79 of them were up regulated and 6 genes were down regulated with antiprogestin 
mifepristone treatment. The 132 differentially expressed genes in both the stromal and 
epithelial compartment were analyzed for canonical pathways and biological networks using 
bioinformatics tool IPA. The dataset was analyzed for the upstream regulators that are 
responsible for the gene expression changes in the given experimental dataset and it was 
revealed that CBX5 (Chromebox Homolog 5), a transcription factor, was inhibited whereas 
CSF2 (Colony stimulating Factor 2) and EBF1 (early B cell Factor 1) were activated, based 
on the Z-scores calculated by the IPA. 
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These microarray findings were revalidated by RTPCR and IHC analysis for selected 
genes based on the importance and availability of the antibodies. RTPCR was done for 13 
selected genes in stromal compartment and 11 in glandular compartment and is in line with 
the microarray findings (Table 3). We found a gene of interest, ENPP3 that is downregulated 
by 55-fold in the stromal compartment and 9-fold in epithelial compartment by RTPCR 
analysis. 7 genes were selected to study by IHC and found that except ENPP3, none of them 
were significantly regulated between the groups. Immunostaining for ENPP3 was seen in all 
the samples of control group and statistical analysis demonstrated a significant down 
regulation in the treatment group (p=0.0007).  
 
Table 3: Validation of microarray results of selected genes that were differentially regulated 
with P inhibition by RTPCR both in the endometrial stromal and glandular compartments 
Stromal Compartment Glandular Compartment 
Gene Fold Change P Value Gene Fold Change P Value 
MT1G -135.552 0.0082* MT1G -519.598 0.0053* 
ENPP3 -55.928 0.0348* ENPP3 -9.465 0.0155* 
MT2A -3.514 0.0307* MT2A -7.016 0.0028* 
SFRP4 8.769 0.0128* UBE2E2 7.052 0.0237* 
CPM 29.055 0.0051* SFRP4 16.251 0.0001* 
SOD2 -1.472 0.3399 RPL27A 4.262 0.0955 
BCL11A -1.212 0.3785 BCL11A 8.302 0.1318 
ATP6V0E1 1.277 0.2270 POSTN 2.686 0.3518 
HMGN5 -1.092 0.8519 STC1 -5.498 0.4030 
SNORA3 -1.268 0.8885 RHOJ 1.480 0.6211 
RPL27A 1.127 0.9000 VPS53 1.073 0.9423 
SMARCA1 1.593 0.9581 
   CTSC 1.993 0.1981 
   * p value < 0.05 
 
We investigated the expression of ENPP3 in the endometrium and found it to be 
significantly down regulated by 59-fold in the epithelial compartment in microarray (p=0.04) 
in the mifepristone treated group. ENPP3 expression as analyzed by IHC, was localized at the 
apical surface of the epithelium in the luminal and glandular epithelium, very scanty 
expression was seen in the glands of treatment group. In contrast, ENPP3 expression was not 
seen in the stromal compartment either in the receptive or non-receptive endometrium by 
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immunohistochemical analysis and western blot, although its expression was seen at mRNA 
level in the stromal compartment. Further, we discovered that ENPP3 shows a cyclical 
expression in menstrual cycle, being highest during the WOI and least in the proliferative 
phase, an expression similar to progesterone secretion. Statistical significance was seen in the 
expression of ENPP3 in mid secretory phase compared to proliferative phase (p=0.0001), 
however, no significant difference is seen between mid secretory and late secretory phase as 
analyzed by IHC technique.  
Furthermore, we investigated the ENPP3 expression in the uterine lavages and 
endometrial tissue lysates by completely automated western blot. A strong immunoband was 
observed at 165kD rather than at 100kD both in the uterine lavages and endometrial tissue 
lysates indicating glycosylated form of ENPP3. A significant down regulation was seen in the 
treatment group of both uterine fluid (p=0.002) and tissue lysates (p=0.002), however, 
abundant expression of ENPP3 is found in the tissue lysates compared to the uterine lavages. 
Thereafter, we have evaluated and confirmed that ENPP3 exists in the glycosylated form by 
deglycosylation using PNGase-F enzyme, which cleaves the glycoaminidase link and were 
evaluated again by western blot. A shift in the immunoband from 165kd to 110kd was 
observed in the deglycosylated samples, confirming the existence of ENPP3 in glycosylated 
form. We also analyzed the uterine fluid from receptive and non-receptive phase for 
quantifying ENPP3 expression by nano-ESI-LC/MS/MS and discovered ENPP3 to be 
upregulated in the progesterone dominant endometrium by 35-fold with respect to non-
receptive phase (LH+2) uterine fluid. 
Seven of ten blastocysts attached to the endometrial constructs and the expression of 
ENPP3 in these constructs was significantly high compared to the mifepristone treated group 
suggesting a regulation of ENPP3 by progesterone. 
 
4.4.2 Discussion 
In the current study, we showed that ENPP3, a progesterone-regulated factor, is 
expressed in the epithelial glands and uterine secretions and exists in a glycosylated form. 
Also, we demonstrated the regulation of ENPP3 by progesterone in a functional study with 
blastocyst cultures on endometrial 3D cell cultures and treated with antiprogestin. It was 
found that ENPP3 expression was significantly down regulated with inhibition of blastocyst 
implantation in the treatment group. Since a comparable level of endometrial ENPP3 
expression reflects in the uterine fluid, we propose ENPP3 as a progesterone regulated 
endometrial receptivity marker that has potential capability to be used in the non-invasive 
diagnosis of receptivity. However, this hypothesis has to be tested in a clinical setup in 
various fertility disorders like RIF with a large number of patients for validation.  
Several studies have been done using the transcriptomics approach to identify 
potential biomarkers of endometrial receptivity with an aim to translate them into clinical use 
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(240, 265, 266). Interestingly none of these studies and studies that correlated mRNA and 
protein levels during the receptive phase and non-receptive phase have reported the 
expression of ENPP3. Here, for the first time, we report ENPP3 is expressed during the mid 
secretory phase/WOI during which the domination by progesterone is seen in the 
endometrium. In addition, we demonstrated its role in implantation by using a well-
established 3D model, however it would be interesting to explore the specific mechanism of 
action of ENPP3 in receptivity and implantation, particularly in infertile patients. 
The encouraging findings of ENPP3 in uterine fluid makes it a promising marker for 
the diagnosis of endometrial receptivity using uterine fluid sample that could be collected by 
less invasive technique. Moreover, uterine fluid sampling in a cycle where ET is planned 
does not affect the implantation rate or pregnancy (267), hence non-invasive measurement of 
ENPP3 levels in uterine fluid could be of benefit to assess the receptivity of the endometrium 
in the same embryo that of transfer cycle.  
Majority of the studies using omics approach used the endometrial tissue as a whole, 
which gives a cumulative picture of all cell types present in the endometrium. In this study, 
rather than going with the endometrial tissue lysis directly, we used LCMD to specifically 
isolate the major cells of endometrium, stromal and epithelial cells and analyzed the genomic 
signature of these compartments individually, which gives a better representation of 
endometrial receptivity based on specific cell type. Using this approach we have discovered 
ENPP3 that is specific to epithelial compartment and validated the initial microarray findings 
at mRNA and protein level by RTPCR, immunohistochemistry and western blotting 
techniques.  
One of the important limitations with human samples in research is the availability of 
the sample in enough quantity for analysis; normally a sufficient quantity is required for 
protein analysis. Since we had a limited quantity of tissue, this limitation was taken care of by 
utilizing a recently introduced sensitive and specific rapid method of western blot, simple 
Wes. Simple Wes western blot is suitable for analyzing low level of proteins in a very small 
sample since very small quantity of protein could be obtained from the uterine fluid from 
women.  Also, we studied the expression of ENPP3 in both the receptive and non-receptive 
phase of uterine fluid by sensitive, label free protein technology mass spectrometry (nano-
ESI-LC/MS/MS).  
Regulation of ENPP3 in the endometrium is intriguing. Interestingly, mRNA of 
ENPP3 is upregulated by 55-fold change in the stromal compartment of the receptive 
endometrium compared to stromal cells in the non receptive phase endometrium, however 
there is no detectable protein either by immunohistochemistry or by western blot in stromal 
compartment of both the groups. This typical behavior of high mRNA and no protein not 
only reflects the post-translational mechanisms but also may have a biological role that needs 
to be addressed further.  
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ENPP3 expression in the endometrium shows a similar trend to progesterone, being 
highest in the mid secretory phase, followed by late secretory phase and least expressed in the 
proliferative phase suggesting a considerable role in regulation by progesterone and a role in 
endometrial receptivity. Here, we also have shown that ENPP3 is expressed in the 
glycosylated form. Glycosylation is known to play an important role in determining the 
protein structure, stability, function, protein-protein interactions and determines the cellular 
responses to the exogenous factors.  
ENPP3 is a type II transmembrane protein and expression is reported in the mast cells 
and basophils and is considered as a marker of allergic reactions (268). It belongs to the 
ectoenzymes family possessing ATPase and ATP pyrophosphatase activity and is involved in 
hydrolysis of extracellular nucleotides. Recently, it has been shown by Korekane et al. that 
ENPP3 regulates the glycosyltransferase activity that facilitates glycosylation of many 
proteins and can modify the activity of glycans (269). Glycans are also seen in the uterine 
secretions and in endometrium, demonstrating an important role in endometrial receptivity. 
ENPP3 is a newly described molecule in endometrium; hence less is known about its role in 
receptivity. The only protein reported from ENPP family in endometrium is ENPP5, however 
its role is yet to be elucidated (270). 
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5. Limitations  
1. The study in paper 1 is mainly focused only on a single cytokine LIF, its role in embryo 
implantation and endometrial receptivity, however it has to be noted that in vivo the 
implantation process and endometrial receptivity is a complex phenomenon with involvement 
of several cytokines, cell adhesion molecules and other factors. A combination of cytokines 
that are present in the uterine fluid will throw more light in understanding the roles of 
cytokines in human embryo implantation. 
2.Though the 3D endometrial co-culture model used in all the studies is close to in vivo 
human endometrium, still an improvement in the model is needed with the addition of other 
cell types such as uNK, endothelial cells, macrophages and other factors that are seen in the 
natural endometrium. 
3.Assessment of blastocyst attachment to the constructs is done by washing the cultures at the 
time of culture termination after 5 days; this may risk the loosely attached blastocysts to the 
constructs, so developing a better imaging techniques to visualize the adhesion gives more 
valuable information. 
4. Scarcity in getting timed endometrial biopsies from fertile women without any 
contraception use and embryos for research purpose makes an important limitation for using 
small sample size in all the studies. 
5. The 3D endometrial co-culture model is only limited to the attachment phase of the 
implantation and in depth analysis of post attachment events could give valuable information 
of UPA in regard to the endometrial receptivity and implantation. Hence, further modification 
of the model is needed to study the mechanism of implantation apart from the adhesion 
phase. 
6. Gene expression analysis by RTPCR in papers 2-4 is a cumulative result of both the 
stromal and epithelial cells present in the co-culture that may not give a true picture of 
molecular expression from the specific cell types in the endometrium. Thus, isolating the 
stromal and epithelial cells separately from the constructs and analysis would be highly 
significant. 
7. In in vivo conditions, the drugs are metabolized by liver and are cleared from the 
circulation, however this mechanism is absent in any in vitro model that marks an important 
general limitation in studying the dose responses of a given drug. 
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6. Conclusions  
 
1. We have shown a critical role of LIF on the viability of the blastocyst by using LIF 
inhibitor, PEGLA in a well-established 3D endometrial cell co-culture model. 
 
2. UPA dosage used in emergency contraception (30mg single dose) does not affect 
endometrial receptivity and embryo implantation, although few biomarkers involved 
in endometrial receptivity and implantation process are altered to a minor extent as 
studied  in vitro. 
 
3. Mifepristone in a dose of 0.5µM successfully inhibited implantation of the human 
embryos in the co-cultures by affecting endometrial receptivity; most of the studied 
receptivity biomarkers were significantly down regulated with 0.5µM mifepristone. 
However, 0.05µM mifepristone affected the endometrial receptivity with no effect on 
implantation of human blastocysts in vitro. 
 
4. ENPP3 is proposed as a molecular marker for progesterone regulated endometrial 
receptivity.  
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7. Future directions 
 
1. Our findings have opened new potential for using PEGLA as a non-steroidal 
fertility regulating agent. 
 
2. The knowledge on the role of LIF in the embryo survival mechanisms may help 
infertile women with uterine LIF deficiencies in improving the pregnancy rates. 
 
3. Addition of LIF to the culture media may help in obtaining an increased rate of 
healthy embryos 
 
4. In a low dose regimen, mifepristone could be developed as an on demand 
contraceptive. 
 
5. Findings with ENPP3 could be used in developing a less invasive diagnostic test 
for diagnosing progesterone regulated endometrial receptivity that may help in 
screening woman seeking IVF treatment for their endometrial receptivity.  
 
6. Further study the functional role of ENPP3 in endometrial receptivity and embryo 
implantation process 
 
7. An inhibitor or molecule that alters the function of ENPP3 could be developed and 
potentially used for fertility regulation. 
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